{"protocolSection":{"identificationModule":{"nctId":"NCT04232280","orgStudyIdInfo":{"id":"mRNA-1647-P202"},"organization":{"fullName":"ModernaTX, Inc.","class":"INDUSTRY"},"briefTitle":"Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults","officialTitle":"A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults"},"statusModule":{"statusVerifiedDate":"2026-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-01-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-01-04","type":"ACTUAL"},"completionDateStruct":{"date":"2023-01-04","type":"ACTUAL"},"studyFirstSubmitDate":"2020-01-09","studyFirstSubmitQcDate":"2020-01-14","studyFirstPostDateStruct":{"date":"2020-01-18","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-12-18","resultsFirstSubmitQcDate":"2026-05-01","resultsFirstPostDateStruct":{"date":"2026-05-05","type":"ACTUAL"},"dispFirstSubmitDate":"2023-12-29","dispFirstPostDateStruct":{"date":"2026-05-05","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-05-01","lastUpdatePostDateStruct":{"date":"2026-05-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"ModernaTX, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.","detailedDescription":"mRNA-1647-P202 is a 2-part study. Part 1 of the study evaluates the safety and immunogenicity of 3 dose levels of mRNA-1647 vaccine or placebo, administered on a 0, 2, 6-month schedule in healthy CMV-seronegative and CMV-seropositive males and females, 18 to 40 years of age. A planned interim analysis of safety and immunogenicity through Month 3 (1 month after the second dose) of Part 1 of the study informed the selection of the middle dose level for further development. Part 2 of the study is designed to further evaluate the safety and immunogenicity of the middle dose level of mRNA-1647 vaccine or placebo on a 0, 2, 6-month schedule in approximately 200 healthy participants 18 to 40 years of age, comprised of CMV-seronegative and CMV-seropositive female population, which includes the target population for the pivotal Phase 3 efficacy trial."},"conditionsModule":{"conditions":["Cytomegalovirus Infection"],"keywords":["Moderna","mRNA-1647","Cytomegalovirus","CMV","Cytomegalovirus Vaccine","Cytomegalovirus Infections","Cytomegalovirus Congenital","Virus Diseases","Infection Viral","DNA Virus Infections","Messenger RNA"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","maskingDescription":"Observer-Blind","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":315,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"mRNA-1647 Dose Level A","type":"EXPERIMENTAL","description":"Participants will receive mRNA-1647 vaccine at Dose Level A by intramuscular (IM) injection on Day 1, Day 56, and Day 168.","interventionNames":["Biological: mRNA-1647"]},{"label":"mRNA-1647 Dose Level B","type":"EXPERIMENTAL","description":"Participants will receive mRNA-1647 vaccine at Dose Level B by IM injection on Day 1, Day 56, and Day 168.","interventionNames":["Biological: mRNA-1647"]},{"label":"mRNA-1647 Dose Level C","type":"EXPERIMENTAL","description":"Participants will receive mRNA-1647 vaccine at Dose Level C by IM injection on Day 1, Day 56, and Day 168.","interventionNames":["Biological: mRNA-1647"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive placebo matching to the mRNA-1647 vaccine dose by IM injection on Day 1, Day 56, and Day 168.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"mRNA-1647","description":"Lyophilized product that is reconstituted with saline then diluted with a special diluent to reach the desired concentration","armGroupLabels":["mRNA-1647 Dose Level A","mRNA-1647 Dose Level B","mRNA-1647 Dose Level C"]},{"type":"OTHER","name":"Placebo","description":"0.9% sodium chloride (normal saline) injection","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)","description":"Solicited ARs were selected signs and symptoms occurring after vaccination administration during a specified post-vaccination follow-up period. The occurrence and intensity of the selected signs and symptoms was actively solicited from the participant during a specified post-vaccination follow-up period (day of vaccination and 6 subsequent days), using a predefined checklist in the electronic diary. The following local ARs were solicited: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the vaccination arm. The following systemic ARs were solicited: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, fever, and chills. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.","timeFrame":"Up to Day 175 (7 days following last dose administration)"},{"measure":"Number of Participants With Unsolicited Adverse Events (AEs)","description":"An unsolicited AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. The treatment-emergent AEs are defined as any event not present before exposure to study drug or any event already present that worsened in intensity or frequency after exposure. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.\"","timeFrame":"Up to Day 196 (28 days following last dose administration)"},{"measure":"Number of Participants With Medically Attended Adverse Events (MAAEs)","description":"An MAAE is an AE that lead to a visit to a healthcare practitioner (HCP). This would include visits to study clinic for unscheduled assessments (for example, rash assessment, abnormal laboratory follow-up), and visits to HCPs external to the clinical site (for example, urgent care, primary care physician). A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.\"","timeFrame":"Up to Day 336 (6 months following last dose administration)"},{"measure":"Number of Participants With Serious Adverse Events (SAEs)","description":"An SAE was defined as any untoward medical occurrence that, in the view of either the Investigator or the Sponsor, resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization (hospitalization or prolongation of hospitalization in the absence of a precipitating event was not in itself an SAE), resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.\"","timeFrame":"Up to Day 504 (1 year following last dose administration)"},{"measure":"Geometric Mean Titer (GMT) of Serum Neutralizing Anti-CMV Antibodies Against Epithelial Cell Infection and Against Fibroblast Infection","description":"Blood samples for antibody-mediated immunogenicity (AMI) analysis were collected during protocol-specified study visits. Serological assessment of serum anti-CMV neutralizing antibody titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay. Results are reported as fold dilution (titer). GMT 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.","timeFrame":"Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504"},{"measure":"Geometric Mean Ratio (GMR) of Serum Neutralizing Anti-CMV Antibodies Against Epithelial Cell Infection and Against Fibroblast Infection","description":"Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits. Serological assessment of serum anti-CMV neutralizing antibody titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay. The GMR measures the changes in immunogenicity titers within participants. Results are reported as a ratio (post-baseline/baseline titers). GMR 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.","timeFrame":"Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504"},{"measure":"Percentage of Participants With ≥2-Fold, 3-Fold, and 4-Fold Increases in Neutralizing Antibodies (nAb) Over Baseline Against Epithelial Cell Infection and Against Fibroblast Infection","description":"Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits. Serological assessment of serum anti-CMV nAb titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay. A ≥z-fold increase from baseline at participant level was defined as a ≥z \\* the lower limit of quantification (LLOQ) for participants with baseline antibody level below the LLOQ, or a z-times or higher-level ratio in participants with baseline antibody level equal to or above the LLOQ. LLOQ=16. Results are reported as percentage of participants with ≥2-fold, 3-fold, and 4-fold increases in serum anti-CMV nAb titers from baseline. 95% CI for percentage is calculated using the Clopper-Pearson method.","timeFrame":"Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504"}],"secondaryOutcomes":[{"measure":"GMT of Anti-Glycoprotein B (gB)-Specific Immunoglobulin G (IgG) and Anti-Pentamer-specific IgG as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) of Post-Baseline/Baseline Titers","description":"Blood samples for antibody-mediated immunogenicity were collected during protocol-specified study visits. Serological assessment for anti-gB-specific IgG and anti-pentameric gH/gL/UL128/UL130/UL131A glycoprotein complex (Pentamer)-specific IgG binding was measured with ELISA. The GMT measures the level of inhibition of anti-gB-specific IgG (anti-gB) and anti-Pentamer-specific IgG (anti-Pentamer) against cytomegalovirus. Results are reported as fold dilution (titer). GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.","timeFrame":"Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504"},{"measure":"GMR of Anti-gB-specific IgG and Anti-Pentamer-specific IgG as Measured by ELISA of Post-Baseline/Baseline Titers","description":"Blood samples for antibody-mediated immunogenicity were collected during protocol-specified study visits. Serological assessment for anti-gB-specific IgG and anti-Pentamer-specific IgG binding was measured with ELISA. The GMR measures the changes in immunogenicity titers within participants. Results are reported as a ratio (post-baseline/baseline titers). GMR 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation. Number Analyzed = participants who were evaluable at specified timepoints.","timeFrame":"Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504"},{"measure":"GMT of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection at Each Timepoint, in the CMV-Seropositive Group and in the CMV-Seronegative Group","description":"Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits. Serological assessment of serum anti-CMV nAb titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay. Results are reported as fold dilution (titer). GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.","timeFrame":"Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504"},{"measure":"GMR of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection at Each Timepoint, in the CMV-Seropositive Group and in the CMV-Seronegative Group","description":"Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits. Serological assessment of serum anti-CMV nAb titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay. The GMR measures the changes in immunogenicity titers within participants. Results are reported as a ratio (post-baseline/baseline titers). GMR 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.","timeFrame":"Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504"},{"measure":"Percentage of Participants With ≥2-Fold, 3-Fold, and 4-Fold Increases Over Baseline of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection in the CMV-Seropositive and CMV-Seronegative Groups","description":"Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits. Serological assessment of serum anti-CMV nAb titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay. A ≥z-fold increase from baseline at participant level was defined as a ≥z \\* the LLOQ for participants with baseline antibody level below the LLOQ, or a z-times or higher-level ratio in participants with baseline antibody level equal to or above the LLOQ. LLOQ=16. Results are reported as percentage of participants with ≥2-fold, 3-fold, and 4-fold increases in serum anti-CMV nAb titers from baseline. 95% CI for percentage is calculated using the Clopper-Pearson method.","timeFrame":"Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504"},{"measure":"GMT of Antigen-Specific IgG (ELISA) at Each Timepoint in the CMV-Seropositive and CMV-Seronegative Groups","description":"Blood samples for antibody-mediated immunogenicity were collected during protocol-specified study visits. Serological assessment for anti-gB-specific IgG and anti-Pentamer-specific IgG binding was measured with ELISA. Results are reported as fold dilution (titer). GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.","timeFrame":"Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504"},{"measure":"GMR of Antigen-Specific IgG (ELISA) at Each Timepoint in the CMV-Seropositive and CMV-Seronegative Groups","description":"Blood samples for antibody-mediated immunogenicity were collected during protocol-specified study visits. Serological assessment for anti-gB-specific IgG and anti-Pentamer-specific IgG binding was measured with ELISA. The GMR measures the changes in immunogenicity titers within participants. Results are reported as a ratio (post-baseline/baseline titers). GMR 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.","timeFrame":"Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female 18-40 years of age (Part 1); Female 18-40 years of age (Part 2)\n* Understands and agrees to comply with the trial procedures and provides written informed consent\n* According to the assessment of the Investigator, is in good general health and is capable of complying with trial procedures\n* Body mass index (BMI) 18-35 kilograms/meter (kg/m\\^2)\n* Female participants must either be of non-childbearing potential or use acceptable methods of contraception from at least 28 days prior to the first vaccination and through 3 months following last vaccination and is not breastfeeding.\n* Male participants must agree to practice adequate contraception from the time of the first vaccination and through 3 months after the last vaccination.\n\nExclusion Criteria:\n\n* Acutely ill or febrile on the day of the first vaccination\n* Prior receipt of any CMV vaccine\n* Abnormal screening safety laboratory test results\n* Diagnosis or condition that, in the judgment of Investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to trial procedures\n* Has received or plans to receive a vaccine ≤28 days prior to the first vaccination or plans to receive a non-study vaccine within 28 days prior to or after any study vaccination, except for any licensed influenza vaccine which can be administered \\>14 days before or after any study vaccination. COVID-19 vaccines (regardless of manufacturer) may be administered \\>7 days but preferably \\>14 days before or after any study vaccination, with the intention of prioritizing COVID-19 vaccination over all other considerations.\n* Prior receipt of chronic systemic immunosuppressants or immune-modifying drugs\n* Receipt of intravenous immunoglobulins or plasma products within 3 months prior to the day of the first study vaccination\n* Previous receipt of medications in lipid nanoparticle (LNP) formulation (Part 1 participants only)\n* Has donated ≥450 milliliters (mL) of blood products within 28 days of the Screening visit\n* Participated in an interventional clinical trial within 28 days prior to the day of enrollment\n* Is an immediate family member or household member of trial personnel","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Benchmark Research","city":"Sacramento","state":"California","zip":"95864","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"Optimal Research","city":"Peoria","state":"Illinois","zip":"61614","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"Johnson County Clin-Trials","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"Alliance for Multispecialty Research","city":"Lexington","state":"Kentucky","zip":"40509","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Aventiv Research Inc","city":"Columbus","state":"Ohio","zip":"43213-6523","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Tekton Research Inc","city":"Austin","state":"Texas","zip":"78745","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Crossroads Clinical Research","city":"Victoria","state":"Texas","zip":"77901","country":"United States","geoPoint":{"lat":28.80527,"lon":-97.0036}},{"facility":"Foothill Family Clinic","city":"Salt Lake City","state":"Utah","zip":"84109","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Foothill Family Clinic-South Clinic","city":"Salt Lake City","state":"Utah","zip":"84121","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}}]},"referencesModule":{"references":[{"pmid":"38190492","type":"DERIVED","citation":"Galiza EP, Khalil A, Heath PT. Update on Vaccines in Antenatal Care. Pediatr Infect Dis J. 2024 Feb 1;43(2):e60-e62. doi: 10.1097/INF.0000000000004183. Epub 2023 Dec 27. No abstract available."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Data were collected based on participant serostatus and the treatment group to which the participant was randomized regardless of the part of the study.","recruitmentDetails":"mRNA-1647-P202 was a 2-part study. For Part 1, participants were randomized to receive 1 of 3 dose levels (50, 100, 150 micrograms \\[ug\\]) of the mRNA-1647 vaccine and placebo in CMV-seronegative and CMV-seropositive male and female participants.\n\nFor Part 2, new female participants (that is, did not participate in Part 1) who were either CMV-seronegative or CMV-seropositive were randomized to receive either the mRNA-1647 vaccine (100 ug) or placebo.","groups":[{"id":"FG000","title":"Seronegative mRNA-1647 (50 ug)","description":"Cytomegalovirus (CMV)-seronegative participants received mRNA-1647 (50 ug) by intramuscular (IM) injection on Day 1, Day 56, and Day 168."},{"id":"FG001","title":"Seronegative mRNA-1647 (100 ug)","description":"CMV-seronegative participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"FG002","title":"Seronegative mRNA-1647 (150 ug)","description":"CMV-seronegative participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"FG003","title":"Seronegative Placebo","description":"CMV-seronegative participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."},{"id":"FG004","title":"Seropositive mRNA-1647 (50 ug)","description":"CMV-seropositive participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"FG005","title":"Seropositive mRNA-1647 (100 ug)","description":"CMV-seropositive participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"FG006","title":"Seropositive mRNA-1647 (150 ug)","description":"CMV-seropositive participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"FG007","title":"Seropositive Placebo","description":"CMV-seropositive participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","comment":"Randomized Set: all participants who were randomized in the study, regardless of the participant's treatment status in the study. Participants were included in the treatment group to which they were randomized.","achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"73"},{"groupId":"FG002","numSubjects":"45"},{"groupId":"FG003","numSubjects":"55"},{"groupId":"FG004","numSubjects":"18"},{"groupId":"FG005","numSubjects":"36"},{"groupId":"FG006","numSubjects":"18"},{"groupId":"FG007","numSubjects":"25"}]},{"type":"Received At Least 1 Dose Of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"73"},{"groupId":"FG002","numSubjects":"45"},{"groupId":"FG003","numSubjects":"55"},{"groupId":"FG004","numSubjects":"18"},{"groupId":"FG005","numSubjects":"36"},{"groupId":"FG006","numSubjects":"18"},{"groupId":"FG007","numSubjects":"25"}]},{"type":"Safety Set","comment":"All randomized participants who received any study vaccination. Safety data were collected based on the treatment a participant received, regardless of the part of the study.","achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"72"},{"groupId":"FG002","numSubjects":"45"},{"groupId":"FG003","numSubjects":"53"},{"groupId":"FG004","numSubjects":"18"},{"groupId":"FG005","numSubjects":"37"},{"groupId":"FG006","numSubjects":"18"},{"groupId":"FG007","numSubjects":"27"}]},{"type":"Full Analysis Set (FAS)","comment":"Participants who a) received any study injection, b) had baseline (Day 1) data available for those analyses that required baseline data, and c) had at least 1 post-injection assessment for the analysis endpoint. Participants were included in the injection group to which they were randomized.","achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"68"},{"groupId":"FG002","numSubjects":"45"},{"groupId":"FG003","numSubjects":"55"},{"groupId":"FG004","numSubjects":"15"},{"groupId":"FG005","numSubjects":"34"},{"groupId":"FG006","numSubjects":"17"},{"groupId":"FG007","numSubjects":"23"}]},{"type":"Part 1 Participants","achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"45"},{"groupId":"FG002","numSubjects":"45"},{"groupId":"FG003","numSubjects":"45"},{"groupId":"FG004","numSubjects":"18"},{"groupId":"FG005","numSubjects":"18"},{"groupId":"FG006","numSubjects":"18"},{"groupId":"FG007","numSubjects":"18"}]},{"type":"Part 2 (Female Participants Only)","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"28"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"18"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"7"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"34"},{"groupId":"FG001","numSubjects":"52"},{"groupId":"FG002","numSubjects":"35"},{"groupId":"FG003","numSubjects":"47"},{"groupId":"FG004","numSubjects":"15"},{"groupId":"FG005","numSubjects":"28"},{"groupId":"FG006","numSubjects":"13"},{"groupId":"FG007","numSubjects":"18"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"7"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"3"},{"groupId":"FG007","numSubjects":"4"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"2"}]},{"type":"Participant No Longer Eligible","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}]},{"type":"Non-compliance","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Randomized Set: all participants who were randomized in the study, regardless of the participant's treatment status in the study. Participants were included in the treatment group to which they were randomized.","groups":[{"id":"BG000","title":"Seronegative mRNA-1647 (50 ug)","description":"CMV-seronegative participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"BG001","title":"Seronegative mRNA-1647 (100 ug)","description":"CMV-seronegative participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"BG002","title":"Seronegative mRNA-1647 (150 ug)","description":"CMV-seronegative participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"BG003","title":"Seronegative Placebo","description":"CMV-seronegative participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."},{"id":"BG004","title":"Seropositive mRNA-1647 (50 ug)","description":"CMV-seropositive participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"BG005","title":"Seropositive mRNA-1647 (100 ug)","description":"CMV-seropositive participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"BG006","title":"Seropositive mRNA-1647 (150 ug)","description":"CMV-seropositive participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"BG007","title":"Seropositive Placebo","description":"CMV-seropositive participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."},{"id":"BG008","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"73"},{"groupId":"BG002","value":"45"},{"groupId":"BG003","value":"55"},{"groupId":"BG004","value":"18"},{"groupId":"BG005","value":"36"},{"groupId":"BG006","value":"18"},{"groupId":"BG007","value":"25"},{"groupId":"BG008","value":"315"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29.6","spread":"7.07"},{"groupId":"BG001","value":"28.6","spread":"6.88"},{"groupId":"BG002","value":"28.7","spread":"6.10"},{"groupId":"BG003","value":"28.0","spread":"6.67"},{"groupId":"BG004","value":"34.3","spread":"4.54"},{"groupId":"BG005","value":"30.8","spread":"6.53"},{"groupId":"BG006","value":"33.1","spread":"6.41"},{"groupId":"BG007","value":"27.8","spread":"6.32"},{"groupId":"BG008","value":"29.4","spread":"6.71"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"37"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"29"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"21"},{"groupId":"BG008","value":"206"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"109"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"55"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"45"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"29"},{"groupId":"BG006","value":"17"},{"groupId":"BG007","value":"17"},{"groupId":"BG008","value":"259"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"6"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"2"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"33"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"37"},{"groupId":"BG003","value":"47"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"27"},{"groupId":"BG006","value":"14"},{"groupId":"BG007","value":"22"},{"groupId":"BG008","value":"265"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"7"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)","description":"Solicited ARs were selected signs and symptoms occurring after vaccination administration during a specified post-vaccination follow-up period. The occurrence and intensity of the selected signs and symptoms was actively solicited from the participant during a specified post-vaccination follow-up period (day of vaccination and 6 subsequent days), using a predefined checklist in the electronic diary. The following local ARs were solicited: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the vaccination arm. The following systemic ARs were solicited: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, fever, and chills. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.","populationDescription":"Solicited Safety Set: All participants who were randomized, received any study vaccination, and contributed any solicited AR data. Safety data were collected based on the treatment a participant received, regardless of the part of the study.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 175 (7 days following last dose administration)","groups":[{"id":"OG000","title":"Seronegative mRNA-1647 (50 ug)","description":"CMV-seronegative participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG001","title":"Seronegative mRNA-1647 (100 ug)","description":"CMV-seronegative participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG002","title":"Seronegative mRNA-1647 (150 ug)","description":"CMV-seronegative participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG003","title":"Seronegative Placebo","description":"CMV-seronegative participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."},{"id":"OG004","title":"Seropositive mRNA-1647 (50 ug)","description":"CMV-seropositive participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG005","title":"Seropositive mRNA-1647 (100 ug)","description":"CMV-seropositive participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG006","title":"Seropositive mRNA-1647 (150 ug)","description":"CMV-seropositive participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG007","title":"Seropositive Placebo","description":"CMV-seropositive participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"37"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"27"}]}],"classes":[{"title":"After First Vaccination: Solicited Local ARs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"37"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"7"}]}]},{"title":"After First Vaccination: Solicited Systemic ARs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"37"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"16"},{"groupId":"OG007","value":"15"}]}]},{"title":"After Second Vaccination: Solicited Local ARs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"30"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"1"}]}]},{"title":"After Second Vaccination: Solicited Systemic ARs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"31"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"11"}]}]},{"title":"After Third Vaccination: Solicited Local ARs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"1"}]}]},{"title":"After Third Vaccination: Solicited Systemic ARs","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"45"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"7"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Unsolicited Adverse Events (AEs)","description":"An unsolicited AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. The treatment-emergent AEs are defined as any event not present before exposure to study drug or any event already present that worsened in intensity or frequency after exposure. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.\"","populationDescription":"Safety Set: All randomized participants who received any study vaccination. Safety data were collected based on the treatment a participant received, regardless of the part of the study.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 196 (28 days following last dose administration)","groups":[{"id":"OG000","title":"Seronegative mRNA-1647 (50 ug)","description":"CMV-seronegative participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG001","title":"Seronegative mRNA-1647 (100 ug)","description":"CMV-seronegative participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG002","title":"Seronegative mRNA-1647 (150 ug)","description":"CMV-seronegative participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG003","title":"Seronegative Placebo","description":"CMV-seronegative participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."},{"id":"OG004","title":"Seropositive mRNA-1647 (50 ug)","description":"CMV-seropositive participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG005","title":"Seropositive mRNA-1647 (100 ug)","description":"CMV-seropositive participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG006","title":"Seropositive mRNA-1647 (150 ug)","description":"CMV-seropositive participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG007","title":"Seropositive Placebo","description":"CMV-seropositive participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"37"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"10"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Medically Attended Adverse Events (MAAEs)","description":"An MAAE is an AE that lead to a visit to a healthcare practitioner (HCP). This would include visits to study clinic for unscheduled assessments (for example, rash assessment, abnormal laboratory follow-up), and visits to HCPs external to the clinical site (for example, urgent care, primary care physician). A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.\"","populationDescription":"Safety Set: All randomized participants who received any study vaccination. Safety data were collected based on the treatment a participant received, regardless of the part of the study.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 336 (6 months following last dose administration)","groups":[{"id":"OG000","title":"Seronegative mRNA-1647 (50 ug)","description":"CMV-seronegative participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG001","title":"Seronegative mRNA-1647 (100 ug)","description":"CMV-seronegative participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG002","title":"Seronegative mRNA-1647 (150 ug)","description":"CMV-seronegative participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG003","title":"Seronegative Placebo","description":"CMV-seronegative participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."},{"id":"OG004","title":"Seropositive mRNA-1647 (50 ug)","description":"CMV-seropositive participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG005","title":"Seropositive mRNA-1647 (100 ug)","description":"CMV-seropositive participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG006","title":"Seropositive mRNA-1647 (150 ug)","description":"CMV-seropositive participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG007","title":"Seropositive Placebo","description":"CMV-seropositive participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"37"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"9"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAEs)","description":"An SAE was defined as any untoward medical occurrence that, in the view of either the Investigator or the Sponsor, resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization (hospitalization or prolongation of hospitalization in the absence of a precipitating event was not in itself an SAE), resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.\"","populationDescription":"Safety Set: All randomized participants who received any study vaccination. Safety data were collected based on the treatment a participant received, regardless of the part of the study.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Day 504 (1 year following last dose administration)","groups":[{"id":"OG000","title":"Seronegative mRNA-1647 (50 ug)","description":"CMV-seronegative participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG001","title":"Seronegative mRNA-1647 (100 ug)","description":"CMV-seronegative participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG002","title":"Seronegative mRNA-1647 (150 ug)","description":"CMV-seronegative participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG003","title":"Seronegative Placebo","description":"CMV-seronegative participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."},{"id":"OG004","title":"Seropositive mRNA-1647 (50 ug)","description":"CMV-seropositive participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG005","title":"Seropositive mRNA-1647 (100 ug)","description":"CMV-seropositive participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG006","title":"Seropositive mRNA-1647 (150 ug)","description":"CMV-seropositive participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG007","title":"Seropositive Placebo","description":"CMV-seropositive participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"37"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of Serum Neutralizing Anti-CMV Antibodies Against Epithelial Cell Infection and Against Fibroblast Infection","description":"Blood samples for antibody-mediated immunogenicity (AMI) analysis were collected during protocol-specified study visits. Serological assessment of serum anti-CMV neutralizing antibody titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay. Results are reported as fold dilution (titer). GMT 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.","populationDescription":"Per-Protocol Set for AMI: All FAS for AMI participants who a) complied with vaccination schedule, b) complied with timings of blood sampling to have post-vaccination results available for at least 1 assay component, c) had no major protocol deviations that impacted immune response. Number Analyzed=participants evaluable at specified timepoints. Data collected based on participant serostatus and the treatment group to which the participant was randomized regardless of the part of the study.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504","groups":[{"id":"OG000","title":"Seronegative mRNA-1647 (50 ug)","description":"CMV-seronegative participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG001","title":"Seronegative mRNA-1647 (100 ug)","description":"CMV-seronegative participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG002","title":"Seronegative mRNA-1647 (150 ug)","description":"CMV-seronegative participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG003","title":"Seronegative Placebo","description":"CMV-seronegative participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."},{"id":"OG004","title":"Seropositive mRNA-1647 (50 ug)","description":"CMV-seropositive participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG005","title":"Seropositive mRNA-1647 (100 ug)","description":"CMV-seropositive participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG006","title":"Seropositive mRNA-1647 (150 ug)","description":"CMV-seropositive participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG007","title":"Seropositive Placebo","description":"CMV-seropositive participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"23"}]}],"classes":[{"title":"Baseline (Day 1): Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG001","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG002","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG003","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"2250.0","lowerLimit":"589.3","upperLimit":"8591.3"},{"groupId":"OG005","value":"4571.9","lowerLimit":"2708.6","upperLimit":"7717.2"},{"groupId":"OG006","value":"7295.7","lowerLimit":"4109.4","upperLimit":"12952.5"},{"groupId":"OG007","value":"5369.2","lowerLimit":"2514.4","upperLimit":"11465.1"}]}]},{"title":"Day 29: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1120.5","lowerLimit":"684.0","upperLimit":"1835.6"},{"groupId":"OG001","value":"1664.0","lowerLimit":"1032.9","upperLimit":"2680.5"},{"groupId":"OG002","value":"3802.0","lowerLimit":"2712.8","upperLimit":"5328.3"},{"groupId":"OG003","value":"8.9","lowerLimit":"7.2","upperLimit":"11.0"},{"groupId":"OG004","value":"27061.6","lowerLimit":"7391.8","upperLimit":"99073.1"},{"groupId":"OG005","value":"77414.8","lowerLimit":"47189.5","upperLimit":"126999.8"},{"groupId":"OG006","value":"102921.4","lowerLimit":"55936.7","upperLimit":"189371.3"},{"groupId":"OG007","value":"8648.5","lowerLimit":"4823.2","upperLimit":"15507.8"}]}]},{"title":"Day 56: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"875.8","lowerLimit":"546.9","upperLimit":"1402.5"},{"groupId":"OG001","value":"742.0","lowerLimit":"447.3","upperLimit":"1230.8"},{"groupId":"OG002","value":"1814.9","lowerLimit":"1264.2","upperLimit":"2605.3"},{"groupId":"OG003","value":"8.3","lowerLimit":"7.7","upperLimit":"9.0"},{"groupId":"OG004","value":"30228.3","lowerLimit":"7729.8","upperLimit":"118210.8"},{"groupId":"OG005","value":"50596.3","lowerLimit":"27015.5","upperLimit":"94759.9"},{"groupId":"OG006","value":"88938.9","lowerLimit":"50342.7","upperLimit":"157125.5"},{"groupId":"OG007","value":"9365.9","lowerLimit":"5447.7","upperLimit":"16102.0"}]}]},{"title":"Day 84: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61759.1","lowerLimit":"39400.1","upperLimit":"96806.5"},{"groupId":"OG001","value":"44745.1","lowerLimit":"32240.9","upperLimit":"62098.7"},{"groupId":"OG002","value":"49581.0","lowerLimit":"36690.2","upperLimit":"67000.7"},{"groupId":"OG003","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"104605.7","lowerLimit":"67545.8","upperLimit":"161998.9"},{"groupId":"OG005","value":"85821.2","lowerLimit":"53651.2","upperLimit":"137280.7"},{"groupId":"OG006","value":"115517.2","lowerLimit":"72279.5","upperLimit":"184619.6"},{"groupId":"OG007","value":"8684.8","lowerLimit":"5262.2","upperLimit":"14333.5"}]}]},{"title":"Day 168: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8152.7","lowerLimit":"4672.1","upperLimit":"14226.2"},{"groupId":"OG001","value":"10780.1","lowerLimit":"7194.4","upperLimit":"16152.9"},{"groupId":"OG002","value":"9587.3","lowerLimit":"7143.1","upperLimit":"12867.7"},{"groupId":"OG003","value":"9.8","lowerLimit":"6.5","upperLimit":"14.8"},{"groupId":"OG004","value":"41511.4","lowerLimit":"24866.9","upperLimit":"69296.9"},{"groupId":"OG005","value":"48035.5","lowerLimit":"26414.1","upperLimit":"87355.1"},{"groupId":"OG006","value":"81979.3","lowerLimit":"50734.4","upperLimit":"132466.3"},{"groupId":"OG007","value":"9709.3","lowerLimit":"5046.5","upperLimit":"18680.6"}]}]},{"title":"Day 196: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"117022.3","lowerLimit":"71908.7","upperLimit":"190439.0"},{"groupId":"OG001","value":"136935.3","lowerLimit":"97637.3","upperLimit":"192050.2"},{"groupId":"OG002","value":"101113.5","lowerLimit":"75956.7","upperLimit":"134602.1"},{"groupId":"OG003","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"87440.9","lowerLimit":"49755.7","upperLimit":"153669.1"},{"groupId":"OG005","value":"86359.0","lowerLimit":"52162.3","upperLimit":"142974.4"},{"groupId":"OG006","value":"105862.1","lowerLimit":"57020.2","upperLimit":"196540.7"},{"groupId":"OG007","value":"7539.1","lowerLimit":"5062.9","upperLimit":"11226.4"}]}]},{"title":"Day 336: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20622.0","lowerLimit":"13451.7","upperLimit":"31614.3"},{"groupId":"OG001","value":"18790.9","lowerLimit":"13864.4","upperLimit":"25467.9"},{"groupId":"OG002","value":"28526.8","lowerLimit":"18535.4","upperLimit":"43904.1"},{"groupId":"OG003","value":"9.7","lowerLimit":"6.5","upperLimit":"14.4"},{"groupId":"OG004","value":"38787.8","lowerLimit":"23499.4","upperLimit":"64022.7"},{"groupId":"OG005","value":"27083.3","lowerLimit":"17644.7","upperLimit":"41570.9"},{"groupId":"OG006","value":"65788.7","lowerLimit":"37545.8","upperLimit":"115276.4"},{"groupId":"OG007","value":"4992.1","lowerLimit":"3096.2","upperLimit":"8048.8"}]}]},{"title":"Day 504: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10145.3","lowerLimit":"6364.0","upperLimit":"16173.2"},{"groupId":"OG001","value":"11658.5","lowerLimit":"8180.6","upperLimit":"16615.1"},{"groupId":"OG002","value":"15762.9","lowerLimit":"9572.3","upperLimit":"25957.3"},{"groupId":"OG003","value":"12.4","lowerLimit":"7.0","upperLimit":"22.2"},{"groupId":"OG004","value":"23536.1","lowerLimit":"14454.3","upperLimit":"38324.3"},{"groupId":"OG005","value":"18460.9","lowerLimit":"11694.5","upperLimit":"29142.5"},{"groupId":"OG006","value":"51490.6","lowerLimit":"23328.5","upperLimit":"113649.7"},{"groupId":"OG007","value":"5065.0","lowerLimit":"2940.8","upperLimit":"8723.6"}]}]},{"title":"Baseline (Day 1): Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG001","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG002","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG003","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"2507.4","lowerLimit":"651.1","upperLimit":"9655.4"},{"groupId":"OG005","value":"4837.6","lowerLimit":"2865.2","upperLimit":"8167.7"},{"groupId":"OG006","value":"6358.9","lowerLimit":"3624.1","upperLimit":"11157.7"},{"groupId":"OG007","value":"3691.3","lowerLimit":"1716.8","upperLimit":"7936.6"}]}]},{"title":"Day 29: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.2","lowerLimit":"37.7","upperLimit":"116.2"},{"groupId":"OG001","value":"139.4","lowerLimit":"92.6","upperLimit":"209.7"},{"groupId":"OG002","value":"156.0","lowerLimit":"88.7","upperLimit":"274.2"},{"groupId":"OG003","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"5686.3","lowerLimit":"1679.5","upperLimit":"19252.2"},{"groupId":"OG005","value":"11371.6","lowerLimit":"7988.2","upperLimit":"16188.2"},{"groupId":"OG006","value":"20364.9","lowerLimit":"13679.1","upperLimit":"30318.5"},{"groupId":"OG007","value":"6021.3","lowerLimit":"3968.9","upperLimit":"9135.2"}]}]},{"title":"Day 56: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","lowerLimit":"19.8","upperLimit":"57.7"},{"groupId":"OG001","value":"75.3","lowerLimit":"43.7","upperLimit":"129.5"},{"groupId":"OG002","value":"84.2","lowerLimit":"51.2","upperLimit":"138.5"},{"groupId":"OG003","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"5448.5","lowerLimit":"1547.6","upperLimit":"19181.8"},{"groupId":"OG005","value":"9808.0","lowerLimit":"6008.7","upperLimit":"16009.6"},{"groupId":"OG006","value":"11983.0","lowerLimit":"7109.1","upperLimit":"20198.5"},{"groupId":"OG007","value":"6229.1","lowerLimit":"4330.7","upperLimit":"8959.7"}]}]},{"title":"Day 84: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4395.3","lowerLimit":"3194.6","upperLimit":"6047.3"},{"groupId":"OG001","value":"3981.2","lowerLimit":"3126.7","upperLimit":"5069.2"},{"groupId":"OG002","value":"4596.5","lowerLimit":"3437.6","upperLimit":"6146.1"},{"groupId":"OG003","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"10410.2","lowerLimit":"6923.1","upperLimit":"15653.7"},{"groupId":"OG005","value":"10130.3","lowerLimit":"7609.8","upperLimit":"13484.8"},{"groupId":"OG006","value":"12868.2","lowerLimit":"9234.1","upperLimit":"17932.5"},{"groupId":"OG007","value":"7503.9","lowerLimit":"5606.8","upperLimit":"10042.9"}]}]},{"title":"Day 168: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"346.4","lowerLimit":"219.5","upperLimit":"546.6"},{"groupId":"OG001","value":"562.4","lowerLimit":"353.6","upperLimit":"894.7"},{"groupId":"OG002","value":"517.8","lowerLimit":"354.4","upperLimit":"756.5"},{"groupId":"OG003","value":"9.0","lowerLimit":"7.1","upperLimit":"11.5"},{"groupId":"OG004","value":"7447.4","lowerLimit":"3921.5","upperLimit":"14143.7"},{"groupId":"OG005","value":"10185.5","lowerLimit":"6627.2","upperLimit":"15654.3"},{"groupId":"OG006","value":"16061.7","lowerLimit":"11656.7","upperLimit":"22131.2"},{"groupId":"OG007","value":"6155.0","lowerLimit":"4272.1","upperLimit":"8867.9"}]}]},{"title":"Day 196: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2758.2","lowerLimit":"1957.6","upperLimit":"3886.3"},{"groupId":"OG001","value":"3811.4","lowerLimit":"2962.7","upperLimit":"4903.3"},{"groupId":"OG002","value":"3761.2","lowerLimit":"2849.3","upperLimit":"4965.0"},{"groupId":"OG003","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"9013.2","lowerLimit":"5366.4","upperLimit":"15138.0"},{"groupId":"OG005","value":"9170.7","lowerLimit":"6588.8","upperLimit":"12764.2"},{"groupId":"OG006","value":"13122.9","lowerLimit":"9167.8","upperLimit":"18784.3"},{"groupId":"OG007","value":"5392.2","lowerLimit":"3498.0","upperLimit":"8312.3"}]}]},{"title":"Day 336: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1065.0","lowerLimit":"664.7","upperLimit":"1706.2"},{"groupId":"OG001","value":"1168.7","lowerLimit":"807.0","upperLimit":"1692.3"},{"groupId":"OG002","value":"1227.0","lowerLimit":"829.7","upperLimit":"1814.8"},{"groupId":"OG003","value":"9.8","lowerLimit":"6.5","upperLimit":"14.8"},{"groupId":"OG004","value":"8442.3","lowerLimit":"5216.3","upperLimit":"13663.4"},{"groupId":"OG005","value":"8793.6","lowerLimit":"5463.8","upperLimit":"14152.7"},{"groupId":"OG006","value":"11657.2","lowerLimit":"7701.7","upperLimit":"17644.2"},{"groupId":"OG007","value":"4946.9","lowerLimit":"3263.5","upperLimit":"7498.5"}]}]},{"title":"Day 504: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"486.3","lowerLimit":"234.5","upperLimit":"1008.7"},{"groupId":"OG001","value":"582.3","lowerLimit":"355.1","upperLimit":"955.1"},{"groupId":"OG002","value":"817.1","lowerLimit":"526.6","upperLimit":"1267.8"},{"groupId":"OG003","value":"11.6","lowerLimit":"7.1","upperLimit":"19.0"},{"groupId":"OG004","value":"7023.2","lowerLimit":"4003.5","upperLimit":"12320.5"},{"groupId":"OG005","value":"7447.5","lowerLimit":"4216.6","upperLimit":"13153.9"},{"groupId":"OG006","value":"9860.9","lowerLimit":"6933.7","upperLimit":"14023.9"},{"groupId":"OG007","value":"5546.9","lowerLimit":"3761.0","upperLimit":"8181.0"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Ratio (GMR) of Serum Neutralizing Anti-CMV Antibodies Against Epithelial Cell Infection and Against Fibroblast Infection","description":"Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits. Serological assessment of serum anti-CMV neutralizing antibody titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay. The GMR measures the changes in immunogenicity titers within participants. Results are reported as a ratio (post-baseline/baseline titers). GMR 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.","populationDescription":"Per-Protocol Set for AMI: All FAS for AMI participants who a) complied with vaccination schedule, b) complied with timings of blood sampling to have post-vaccination results available for at least 1 assay component, c) had no major protocol deviations that impacted immune response. Number Analyzed=participants evaluable at specified timepoints. Data collected based on participant serostatus and the treatment group to which the participant was randomized regardless of the part of the study.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504","groups":[{"id":"OG000","title":"Seronegative mRNA-1647 (50 ug)","description":"CMV-seronegative participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG001","title":"Seronegative mRNA-1647 (100 ug)","description":"CMV-seronegative participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG002","title":"Seronegative mRNA-1647 (150 ug)","description":"CMV-seronegative participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG003","title":"Seronegative Placebo","description":"CMV-seronegative participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."},{"id":"OG004","title":"Seropositive mRNA-1647 (50 ug)","description":"CMV-seropositive participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG005","title":"Seropositive mRNA-1647 (100 ug)","description":"CMV-seropositive participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG006","title":"Seropositive mRNA-1647 (150 ug)","description":"CMV-seropositive participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG007","title":"Seropositive Placebo","description":"CMV-seropositive participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"23"}]}],"classes":[{"title":"Day 29: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"140.06","lowerLimit":"85.50","upperLimit":"229.45"},{"groupId":"OG001","value":"207.99","lowerLimit":"129.12","upperLimit":"335.06"},{"groupId":"OG002","value":"475.24","lowerLimit":"339.10","upperLimit":"666.04"},{"groupId":"OG003","value":"1.11","lowerLimit":"0.90","upperLimit":"1.38"},{"groupId":"OG004","value":"12.03","lowerLimit":"7.30","upperLimit":"19.83"},{"groupId":"OG005","value":"17.13","lowerLimit":"10.09","upperLimit":"29.10"},{"groupId":"OG006","value":"12.82","lowerLimit":"5.24","upperLimit":"31.37"},{"groupId":"OG007","value":"1.69","lowerLimit":"0.87","upperLimit":"3.29"}]}]},{"title":"Day 56: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"109.47","lowerLimit":"58.36","upperLimit":"175.31"},{"groupId":"OG001","value":"92.75","lowerLimit":"55.92","upperLimit":"153.85"},{"groupId":"OG002","value":"226.86","lowerLimit":"158.03","upperLimit":"328.67"},{"groupId":"OG003","value":"1.04","lowerLimit":"0.96","upperLimit":"1.12"},{"groupId":"OG004","value":"13.43","lowerLimit":"7.55","upperLimit":"23.90"},{"groupId":"OG005","value":"14.61","lowerLimit":"8.03","upperLimit":"26.59"},{"groupId":"OG006","value":"11.89","lowerLimit":"6.07","upperLimit":"23.29"},{"groupId":"OG007","value":"1.74","lowerLimit":"0.79","upperLimit":"3.85"}]}]},{"title":"Day 84: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7719.89","lowerLimit":"4952.02","upperLimit":"12100.81"},{"groupId":"OG001","value":"5593.13","lowerLimit":"4030.12","upperLimit":"7762.34"},{"groupId":"OG002","value":"6197.62","lowerLimit":"4586.28","upperLimit":"8375.09"},{"groupId":"OG003","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"46.49","lowerLimit":"13.06","upperLimit":"165.46"},{"groupId":"OG005","value":"22.34","lowerLimit":"13.11","upperLimit":"38.05"},{"groupId":"OG006","value":"17.06","lowerLimit":"9.58","upperLimit":"30.37"},{"groupId":"OG007","value":"1.65","lowerLimit":"0.80","upperLimit":"3.40"}]}]},{"title":"Day 168: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1019.09","lowerLimit":"584.01","upperLimit":"1778.27"},{"groupId":"OG001","value":"1347.51","lowerLimit":"899.30","upperLimit":"2019.11"},{"groupId":"OG002","value":"1198.41","lowerLimit":"892.89","upperLimit":"1608.47"},{"groupId":"OG003","value":"1.22","lowerLimit":"0.81","upperLimit":"1.85"},{"groupId":"OG004","value":"18.99","lowerLimit":"5.32","upperLimit":"67.77"},{"groupId":"OG005","value":"10.10","lowerLimit":"5.21","upperLimit":"19.61"},{"groupId":"OG006","value":"10.82","lowerLimit":"5.68","upperLimit":"20.62"},{"groupId":"OG007","value":"1.88","lowerLimit":"0.65","upperLimit":"5.40"}]}]},{"title":"Day 196: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14627.79","lowerLimit":"8988.59","upperLimit":"23804.88"},{"groupId":"OG001","value":"17116.91","lowerLimit":"12204.67","upperLimit":"24006.27"},{"groupId":"OG002","value":"12639.18","lowerLimit":"9494.59","upperLimit":"16825.27"},{"groupId":"OG003","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"40.35","lowerLimit":"7.45","upperLimit":"218.58"},{"groupId":"OG005","value":"17.97","lowerLimit":"10.61","upperLimit":"30.44"},{"groupId":"OG006","value":"12.88","lowerLimit":"7.37","upperLimit":"22.49"},{"groupId":"OG007","value":"1.45","lowerLimit":"0.63","upperLimit":"3.33"}]}]},{"title":"Day 336: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2577.75","lowerLimit":"1681.46","upperLimit":"3951.78"},{"groupId":"OG001","value":"2348.86","lowerLimit":"1733.06","upperLimit":"3183.48"},{"groupId":"OG002","value":"3565.85","lowerLimit":"2316.93","upperLimit":"5488.01"},{"groupId":"OG003","value":"1.21","lowerLimit":"0.82","upperLimit":"1.80"},{"groupId":"OG004","value":"17.75","lowerLimit":"4.83","upperLimit":"65.24"},{"groupId":"OG005","value":"5.27","lowerLimit":"3.02","upperLimit":"9.20"},{"groupId":"OG006","value":"8.58","lowerLimit":"3.99","upperLimit":"18.45"},{"groupId":"OG007","value":"1.07","lowerLimit":"0.44","upperLimit":"2.62"}]}]},{"title":"Day 504: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1268.16","lowerLimit":"795.51","upperLimit":"2021.65"},{"groupId":"OG001","value":"1457.31","lowerLimit":"1022.57","upperLimit":"2076.89"},{"groupId":"OG002","value":"1970.37","lowerLimit":"1195.53","upperLimit":"3244.66"},{"groupId":"OG003","value":"1.55","lowerLimit":"0.87","upperLimit":"2.77"},{"groupId":"OG004","value":"10.77","lowerLimit":"3.16","upperLimit":"36.74"},{"groupId":"OG005","value":"3.97","lowerLimit":"2.29","upperLimit":"6.90"},{"groupId":"OG006","value":"6.88","lowerLimit":"2.90","upperLimit":"16.31"},{"groupId":"OG007","value":"0.95","lowerLimit":"0.36","upperLimit":"2.51"}]}]},{"title":"Day 29: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.27","lowerLimit":"4.71","upperLimit":"14.52"},{"groupId":"OG001","value":"17.42","lowerLimit":"11.58","upperLimit":"26.22"},{"groupId":"OG002","value":"19.50","lowerLimit":"11.09","upperLimit":"34.28"},{"groupId":"OG003","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"2.27","lowerLimit":"1.40","upperLimit":"3.66"},{"groupId":"OG005","value":"2.42","lowerLimit":"1.80","upperLimit":"3.25"},{"groupId":"OG006","value":"2.87","lowerLimit":"1.76","upperLimit":"4.67"},{"groupId":"OG007","value":"1.84","lowerLimit":"0.94","upperLimit":"3.59"}]}]},{"title":"Day 56: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.22","lowerLimit":"2.48","upperLimit":"7.21"},{"groupId":"OG001","value":"9.41","lowerLimit":"5.47","upperLimit":"16.19"},{"groupId":"OG002","value":"10.53","lowerLimit":"6.40","upperLimit":"17.32"},{"groupId":"OG003","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"2.19","lowerLimit":"1.43","upperLimit":"3.29"},{"groupId":"OG005","value":"2.13","lowerLimit":"1.59","upperLimit":"2.86"},{"groupId":"OG006","value":"1.68","lowerLimit":"1.04","upperLimit":"2.73"},{"groupId":"OG007","value":"1.81","lowerLimit":"0.84","upperLimit":"3.90"}]}]},{"title":"Day 84: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"549.41","lowerLimit":"399.33","upperLimit":"755.91"},{"groupId":"OG001","value":"497.65","lowerLimit":"390.84","upperLimit":"633.65"},{"groupId":"OG002","value":"574.56","lowerLimit":"429.70","upperLimit":"768.26"},{"groupId":"OG003","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"4.15","lowerLimit":"1.33","upperLimit":"12.94"},{"groupId":"OG005","value":"2.23","lowerLimit":"1.52","upperLimit":"3.27"},{"groupId":"OG006","value":"2.06","lowerLimit":"1.29","upperLimit":"3.27"},{"groupId":"OG007","value":"2.25","lowerLimit":"1.02","upperLimit":"4.97"}]}]},{"title":"Day 168: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43.29","lowerLimit":"27.44","upperLimit":"68.32"},{"groupId":"OG001","value":"70.30","lowerLimit":"44.19","upperLimit":"111.83"},{"groupId":"OG002","value":"64.73","lowerLimit":"44.31","upperLimit":"94.57"},{"groupId":"OG003","value":"1.13","lowerLimit":"0.88","upperLimit":"1.44"},{"groupId":"OG004","value":"3.37","lowerLimit":"0.96","upperLimit":"11.80"},{"groupId":"OG005","value":"1.65","lowerLimit":"1.28","upperLimit":"2.12"},{"groupId":"OG006","value":"2.22","lowerLimit":"1.10","upperLimit":"4.46"},{"groupId":"OG007","value":"2.55","lowerLimit":"0.77","upperLimit":"8.38"}]}]},{"title":"Day 196: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"344.78","lowerLimit":"244.70","upperLimit":"485.79"},{"groupId":"OG001","value":"476.43","lowerLimit":"370.34","upperLimit":"612.91"},{"groupId":"OG002","value":"470.15","lowerLimit":"356.16","upperLimit":"620.63"},{"groupId":"OG003","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"4.20","lowerLimit":"1.06","upperLimit":"16.74"},{"groupId":"OG005","value":"1.67","lowerLimit":"1.21","upperLimit":"2.32"},{"groupId":"OG006","value":"2.02","lowerLimit":"1.07","upperLimit":"3.82"},{"groupId":"OG007","value":"1.90","lowerLimit":"0.80","upperLimit":"4.48"}]}]},{"title":"Day 336: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"133.12","lowerLimit":"86.09","upperLimit":"213.28"},{"groupId":"OG001","value":"146.08","lowerLimit":"100.88","upperLimit":"211.54"},{"groupId":"OG002","value":"153.38","lowerLimit":"103.71","upperLimit":"226.85"},{"groupId":"OG003","value":"1.23","lowerLimit":"0.81","upperLimit":"1.85"},{"groupId":"OG004","value":"3.82","lowerLimit":"1.13","upperLimit":"12.87"},{"groupId":"OG005","value":"1.53","lowerLimit":"1.20","upperLimit":"1.94"},{"groupId":"OG006","value":"1.80","lowerLimit":"0.84","upperLimit":"3.84"},{"groupId":"OG007","value":"1.71","lowerLimit":"0.61","upperLimit":"4.50"}]}]},{"title":"Day 504: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.79","lowerLimit":"29.31","upperLimit":"126.09"},{"groupId":"OG001","value":"72.79","lowerLimit":"44.38","upperLimit":"119.38"},{"groupId":"OG002","value":"103.13","lowerLimit":"65.82","upperLimit":"158.48"},{"groupId":"OG003","value":"1.45","lowerLimit":"0.89","upperLimit":"2.38"},{"groupId":"OG004","value":"3.18","lowerLimit":"0.97","upperLimit":"10.41"},{"groupId":"OG005","value":"1.29","lowerLimit":"1.03","upperLimit":"1.61"},{"groupId":"OG006","value":"1.39","lowerLimit":"0.72","upperLimit":"2.65"},{"groupId":"OG007","value":"2.20","lowerLimit":"0.85","upperLimit":"5.72"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With ≥2-Fold, 3-Fold, and 4-Fold Increases in Neutralizing Antibodies (nAb) Over Baseline Against Epithelial Cell Infection and Against Fibroblast Infection","description":"Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits. Serological assessment of serum anti-CMV nAb titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay. A ≥z-fold increase from baseline at participant level was defined as a ≥z \\* the lower limit of quantification (LLOQ) for participants with baseline antibody level below the LLOQ, or a z-times or higher-level ratio in participants with baseline antibody level equal to or above the LLOQ. LLOQ=16. Results are reported as percentage of participants with ≥2-fold, 3-fold, and 4-fold increases in serum anti-CMV nAb titers from baseline. 95% CI for percentage is calculated using the Clopper-Pearson method.","populationDescription":"Per-Protocol Set for AMI: All FAS for AMI participants who a) complied with vaccination schedule, b) complied with timings of blood sampling to have post-vaccination results available for at least 1 assay component, c) had no major protocol deviations that impacted immune response. Number Analyzed=participants evaluable at specified timepoints. Data collected based on participant serostatus and the treatment group to which the participant was randomized regardless of the part of the study.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504","groups":[{"id":"OG000","title":"Seronegative mRNA-1647 (50 ug)","description":"CMV-seronegative participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG001","title":"Seronegative mRNA-1647 (100 ug)","description":"CMV-seronegative participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG002","title":"Seronegative mRNA-1647 (150 ug)","description":"CMV-seronegative participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG003","title":"Seronegative Placebo","description":"CMV-seronegative participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."},{"id":"OG004","title":"Seropositive mRNA-1647 (50 ug)","description":"CMV-seropositive participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG005","title":"Seropositive mRNA-1647 (100 ug)","description":"CMV-seropositive participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG006","title":"Seropositive mRNA-1647 (150 ug)","description":"CMV-seropositive participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG007","title":"Seropositive Placebo","description":"CMV-seropositive participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"23"}]}],"classes":[{"title":"Day 29: ≥2-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","lowerLimit":"84.5","upperLimit":"99.4"},{"groupId":"OG001","value":"93.8","lowerLimit":"84.8","upperLimit":"98.3"},{"groupId":"OG002","value":"100","lowerLimit":"90.7","upperLimit":"100.0"},{"groupId":"OG003","value":"2.0","lowerLimit":"NA","upperLimit":"10.4","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"100.0","lowerLimit":"78.2","upperLimit":"100.0"},{"groupId":"OG005","value":"93.9","lowerLimit":"79.8","upperLimit":"99.3"},{"groupId":"OG006","value":"84.6","lowerLimit":"54.6","upperLimit":"98.1"},{"groupId":"OG007","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"}]}]},{"title":"Day 29: ≥3-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","lowerLimit":"84.5","upperLimit":"99.4"},{"groupId":"OG001","value":"92.2","lowerLimit":"82.7","upperLimit":"97.4"},{"groupId":"OG002","value":"100.0","lowerLimit":"90.7","upperLimit":"100.0"},{"groupId":"OG003","value":"2.0","lowerLimit":"NA","upperLimit":"10.4","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"93.3","lowerLimit":"68.1","upperLimit":"99.8"},{"groupId":"OG005","value":"87.9","lowerLimit":"71.8","upperLimit":"96.6"},{"groupId":"OG006","value":"84.6","lowerLimit":"54.6","upperLimit":"98.1"},{"groupId":"OG007","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"}]}]},{"title":"Day 29: ≥4-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","lowerLimit":"84.5","upperLimit":"99.4"},{"groupId":"OG001","value":"92.2","lowerLimit":"82.7","upperLimit":"97.4"},{"groupId":"OG002","value":"100.0","lowerLimit":"90.7","upperLimit":"100.0"},{"groupId":"OG003","value":"2.0","lowerLimit":"NA","upperLimit":"10.4","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"86.7","lowerLimit":"59.5","upperLimit":"98.3"},{"groupId":"OG005","value":"84.8","lowerLimit":"68.1","upperLimit":"94.9"},{"groupId":"OG006","value":"84.6","lowerLimit":"54.6","upperLimit":"98.1"},{"groupId":"OG007","value":"9.5","lowerLimit":"1.2","upperLimit":"30.4"}]}]},{"title":"Day 56: ≥2-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","lowerLimit":"86.2","upperLimit":"NA","comment":"Greater than the highest reportable value of 99.9 due to precision"},{"groupId":"OG001","value":"93.8","lowerLimit":"82.8","upperLimit":"98.7"},{"groupId":"OG002","value":"100.0","lowerLimit":"90.0","upperLimit":"100.0"},{"groupId":"OG003","value":"2.4","lowerLimit":"NA","upperLimit":"12.9","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"100.0","lowerLimit":"78.2","upperLimit":"100.0"},{"groupId":"OG005","value":"92.0","lowerLimit":"74.0","upperLimit":"99.0"},{"groupId":"OG006","value":"100.0","lowerLimit":"71.5","upperLimit":"100.0"},{"groupId":"OG007","value":"17.6","lowerLimit":"3.8","upperLimit":"43.4"}]}]},{"title":"Day 56: ≥3-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.4","lowerLimit":"86.2","upperLimit":"NA","comment":"Greater than the highest reportable value of 99.9 due to precision"},{"groupId":"OG001","value":"89.6","lowerLimit":"77.3","upperLimit":"96.5"},{"groupId":"OG002","value":"100.0","lowerLimit":"90.0","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"8.6"},{"groupId":"OG004","value":"100.0","lowerLimit":"78.2","upperLimit":"100.0"},{"groupId":"OG005","value":"84.0","lowerLimit":"63.9","upperLimit":"95.5"},{"groupId":"OG006","value":"90.9","lowerLimit":"58.7","upperLimit":"99.8"},{"groupId":"OG007","value":"5.9","lowerLimit":"0.1","upperLimit":"28.7"}]}]},{"title":"Day 56: ≥4-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","lowerLimit":"82.3","upperLimit":"99.4"},{"groupId":"OG001","value":"87.5","lowerLimit":"74.8","upperLimit":"95.3"},{"groupId":"OG002","value":"100.0","lowerLimit":"90.0","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"8.6"},{"groupId":"OG004","value":"80.0","lowerLimit":"51.9","upperLimit":"95.7"},{"groupId":"OG005","value":"84.0","lowerLimit":"63.9","upperLimit":"95.5"},{"groupId":"OG006","value":"90.9","lowerLimit":"58.7","upperLimit":"99.8"},{"groupId":"OG007","value":"5.9","lowerLimit":"0.1","upperLimit":"28.7"}]}]},{"title":"Day 84: ≥2-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"93.6","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"90.3","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"7.7"},{"groupId":"OG004","value":"100.0","lowerLimit":"78.2","upperLimit":"100.0"},{"groupId":"OG005","value":"100.0","lowerLimit":"88.1","upperLimit":"100.0"},{"groupId":"OG006","value":"100.0","lowerLimit":"75.3","upperLimit":"100.0"},{"groupId":"OG007","value":"15.8","lowerLimit":"3.4","upperLimit":"39.6"}]}]},{"title":"Day 84: ≥3-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"93.6","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"90.3","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"7.7"},{"groupId":"OG004","value":"100.0","lowerLimit":"78.2","upperLimit":"100.0"},{"groupId":"OG005","value":"100.0","lowerLimit":"88.1","upperLimit":"100.0"},{"groupId":"OG006","value":"100.0","lowerLimit":"75.3","upperLimit":"100.0"},{"groupId":"OG007","value":"5.3","lowerLimit":"0.1","upperLimit":"26.0"}]}]},{"title":"Day 84: ≥4-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"93.6","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"90.3","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"7.7"},{"groupId":"OG004","value":"100.0","lowerLimit":"78.2","upperLimit":"100.0"},{"groupId":"OG005","value":"93.1","lowerLimit":"77.2","upperLimit":"99.2"},{"groupId":"OG006","value":"100.0","lowerLimit":"75.3","upperLimit":"100.0"},{"groupId":"OG007","value":"5.3","lowerLimit":"0.1","upperLimit":"26.0"}]}]},{"title":"Day 168: ≥2-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.9","lowerLimit":"83.8","upperLimit":"NA","comment":"Greater than the highest reportable value of 99.9 due to precision"},{"groupId":"OG001","value":"100.0","lowerLimit":"90.3","upperLimit":"200.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.7","upperLimit":"100.0"},{"groupId":"OG003","value":"3.1","lowerLimit":"NA","upperLimit":"16.2","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"100.0","lowerLimit":"76.8","upperLimit":"100.0"},{"groupId":"OG005","value":"100.0","lowerLimit":"82.4","upperLimit":"100.0"},{"groupId":"OG006","value":"90.0","lowerLimit":"55.5","upperLimit":"99.7"},{"groupId":"OG007","value":"21.4","lowerLimit":"4.7","upperLimit":"50.8"}]}]},{"title":"Day 168: ≥3-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.9","lowerLimit":"83.8","upperLimit":"NA","comment":"Greater than the highest reportable value of 99.9 due to precision"},{"groupId":"OG001","value":"100.0","lowerLimit":"90.3","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.7","upperLimit":"100.0"},{"groupId":"OG003","value":"3.1","lowerLimit":"NA","upperLimit":"16.2","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"85.7","lowerLimit":"57.2","upperLimit":"95.2"},{"groupId":"OG005","value":"78.9","lowerLimit":"54.4","upperLimit":"93.9"},{"groupId":"OG006","value":"90.0","lowerLimit":"55.5","upperLimit":"99.7"},{"groupId":"OG007","value":"14.3","lowerLimit":"1.8","upperLimit":"42.8"}]}]},{"title":"Day 168: ≥4-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.9","lowerLimit":"83.8","upperLimit":"NA","comment":"Greater than the highest reportable value of 99.9 due to precision"},{"groupId":"OG001","value":"100.0","lowerLimit":"90.3","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.7","upperLimit":"100.0"},{"groupId":"OG003","value":"3.1","lowerLimit":"NA","upperLimit":"16.2","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"85.7","lowerLimit":"57.2","upperLimit":"98.2"},{"groupId":"OG005","value":"63.2","lowerLimit":"38.4","upperLimit":"83.7"},{"groupId":"OG006","value":"90.0","lowerLimit":"55.5","upperLimit":"99.7"},{"groupId":"OG007","value":"7.1","lowerLimit":"0.2","upperLimit":"33.9"}]}]},{"title":"Day 196: ≥2-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"91.2","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"9.5"},{"groupId":"OG004","value":"100.0","lowerLimit":"75.3","upperLimit":"100.0"},{"groupId":"OG005","value":"95.8","lowerLimit":"78.9","upperLimit":"99.9"},{"groupId":"OG006","value":"100.0","lowerLimit":"71.5","upperLimit":"100.0"},{"groupId":"OG007","value":"16.7","lowerLimit":"3.6","upperLimit":"41.4"}]}]},{"title":"Day 196: ≥3-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"91.2","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"9.5"},{"groupId":"OG004","value":"100.0","lowerLimit":"75.3","upperLimit":"100.0"},{"groupId":"OG005","value":"91.7","lowerLimit":"73.0","upperLimit":"99.0"},{"groupId":"OG006","value":"90.1","lowerLimit":"58.7","upperLimit":"99.8"},{"groupId":"OG007","value":"11.1","lowerLimit":"1.4","upperLimit":"34.7"}]}]},{"title":"Day 196: ≥4-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"91.2","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"9.5"},{"groupId":"OG004","value":"84.6","lowerLimit":"54.6","upperLimit":"98.1"},{"groupId":"OG005","value":"91.7","lowerLimit":"73.0","upperLimit":"99.0"},{"groupId":"OG006","value":"81.8","lowerLimit":"45.2","upperLimit":"97.7"},{"groupId":"OG007","value":"5.6","lowerLimit":"0.1","upperLimit":"27.3"}]}]},{"title":"Day 336: ≥2-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"91.0","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG003","value":"2.9","lowerLimit":"NA","upperLimit":"15.3","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"92.9","lowerLimit":"66.1","upperLimit":"99.8"},{"groupId":"OG005","value":"83.3","lowerLimit":"58.6","upperLimit":"96.4"},{"groupId":"OG006","value":"83.3","lowerLimit":"51.6","upperLimit":"97.9"},{"groupId":"OG007","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"}]}]},{"title":"Day 336: ≥3-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"91.0","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG003","value":"2.9","lowerLimit":"NA","upperLimit":"15.3","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"85.7","lowerLimit":"57.2","upperLimit":"98.2"},{"groupId":"OG005","value":"61.1","lowerLimit":"35.7","upperLimit":"82.7"},{"groupId":"OG006","value":"83.3","lowerLimit":"51.6","upperLimit":"97.9"},{"groupId":"OG007","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"}]}]},{"title":"Day 336: ≥4-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"91.0","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG003","value":"2.9","lowerLimit":"NA","upperLimit":"15.3","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"85.7","lowerLimit":"57.2","upperLimit":"98.2"},{"groupId":"OG005","value":"55.6","lowerLimit":"30.8","upperLimit":"78.5"},{"groupId":"OG006","value":"75.0","lowerLimit":"42.8","upperLimit":"94.5"},{"groupId":"OG007","value":"6.3","lowerLimit":"0.2","upperLimit":"30.2"}]}]},{"title":"Day 504: ≥2-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"84.6","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"90.3","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"85.2","upperLimit":"100.0"},{"groupId":"OG003","value":"5.6","lowerLimit":"0.7","upperLimit":"18.7"},{"groupId":"OG004","value":"92.9","lowerLimit":"66.1","upperLimit":"99.8"},{"groupId":"OG005","value":"64.7","lowerLimit":"38.3","upperLimit":"85.8"},{"groupId":"OG006","value":"81.8","lowerLimit":"48.2","upperLimit":"97.7"},{"groupId":"OG007","value":"6.7","lowerLimit":"0.2","upperLimit":"31.9"}]}]},{"title":"Day 504: ≥3-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"84.6","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"90.3","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"85.2","upperLimit":"100.0"},{"groupId":"OG003","value":"5.6","lowerLimit":"0.7","upperLimit":"18.7"},{"groupId":"OG004","value":"78.6","lowerLimit":"49.2","upperLimit":"95.3"},{"groupId":"OG005","value":"64.7","lowerLimit":"38.3","upperLimit":"85.8"},{"groupId":"OG006","value":"63.9","lowerLimit":"30.8","upperLimit":"89.1"},{"groupId":"OG007","value":"6.7","lowerLimit":"0.2","upperLimit":"31.9"}]}]},{"title":"Day 504: ≥4-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"84.6","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"90.3","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"85.2","upperLimit":"100.0"},{"groupId":"OG003","value":"5.6","lowerLimit":"0.7","upperLimit":"18.7"},{"groupId":"OG004","value":"50.0","lowerLimit":"23.0","upperLimit":"77.0"},{"groupId":"OG005","value":"58.8","lowerLimit":"32.9","upperLimit":"81.5"},{"groupId":"OG006","value":"54.5","lowerLimit":"23.4","upperLimit":"83.3"},{"groupId":"OG007","value":"6.7","lowerLimit":"0.2","upperLimit":"31.9"}]}]},{"title":"Day 29: ≥2-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","lowerLimit":"47.8","upperLimit":"77.6"},{"groupId":"OG001","value":"84.4","lowerLimit":"73.1","upperLimit":"92.2"},{"groupId":"OG002","value":"81.6","lowerLimit":"65.7","upperLimit":"92.3"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"7.0"},{"groupId":"OG004","value":"46.7","lowerLimit":"21.3","upperLimit":"73.4"},{"groupId":"OG005","value":"51.5","lowerLimit":"33.5","upperLimit":"69.2"},{"groupId":"OG006","value":"69.2","lowerLimit":"38.6","upperLimit":"90.9"},{"groupId":"OG007","value":"19.0","lowerLimit":"5.4","upperLimit":"41.9"}]}]},{"title":"Day 29: ≥3-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","lowerLimit":"45.5","upperLimit":"75.6"},{"groupId":"OG001","value":"78.1","lowerLimit":"66.0","upperLimit":"87.5"},{"groupId":"OG002","value":"76.3","lowerLimit":"59.8","upperLimit":"88.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"7.0"},{"groupId":"OG004","value":"20.0","lowerLimit":"4.3","upperLimit":"48.1"},{"groupId":"OG005","value":"33.3","lowerLimit":"18.0","upperLimit":"51.8"},{"groupId":"OG006","value":"38.5","lowerLimit":"13.9","upperLimit":"68.4"},{"groupId":"OG007","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"}]}]},{"title":"Day 29: ≥4-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","lowerLimit":"38.8","upperLimit":"69.6"},{"groupId":"OG001","value":"73.4","lowerLimit":"60.9","upperLimit":"83.7"},{"groupId":"OG002","value":"73.7","lowerLimit":"56.9","upperLimit":"86.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"7.0"},{"groupId":"OG004","value":"13.3","lowerLimit":"1.7","upperLimit":"40.5"},{"groupId":"OG005","value":"21.2","lowerLimit":"9.0","upperLimit":"38.9"},{"groupId":"OG006","value":"23.1","lowerLimit":"5.0","upperLimit":"53.8"},{"groupId":"OG007","value":"14.3","lowerLimit":"3.0","upperLimit":"36.3"}]}]},{"title":"Day 56: ≥2-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"33.4","upperLimit":"66.6"},{"groupId":"OG001","value":"66.7","lowerLimit":"51.6","upperLimit":"79.6"},{"groupId":"OG002","value":"77.1","lowerLimit":"59.9","upperLimit":"89.6"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"8.6"},{"groupId":"OG004","value":"40.0","lowerLimit":"16.3","upperLimit":"67.7"},{"groupId":"OG005","value":"36.0","lowerLimit":"18.0","upperLimit":"57.5"},{"groupId":"OG006","value":"27.3","lowerLimit":"6.0","upperLimit":"61.0"},{"groupId":"OG007","value":"23.5","lowerLimit":"6.8","upperLimit":"49.9"}]}]},{"title":"Day 56: ≥3-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","lowerLimit":"28.6","upperLimit":"61.7"},{"groupId":"OG001","value":"62.5","lowerLimit":"47.4","upperLimit":"76.0"},{"groupId":"OG002","value":"68.6","lowerLimit":"50.7","upperLimit":"83.1"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"8.6"},{"groupId":"OG004","value":"33.3","lowerLimit":"11.8","upperLimit":"61.6"},{"groupId":"OG005","value":"28.0","lowerLimit":"12.1","upperLimit":"49.4"},{"groupId":"OG006","value":"27.3","lowerLimit":"6.0","upperLimit":"61.0"},{"groupId":"OG007","value":"23.5","lowerLimit":"6.8","upperLimit":"49.9"}]}]},{"title":"Day 56: ≥4-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","lowerLimit":"15.4","upperLimit":"45.9"},{"groupId":"OG001","value":"58.3","lowerLimit":"43.2","upperLimit":"72.4"},{"groupId":"OG002","value":"65.7","lowerLimit":"47.8","upperLimit":"80.9"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"8.6"},{"groupId":"OG004","value":"20.0","lowerLimit":"4.3","upperLimit":"48.1"},{"groupId":"OG005","value":"20.0","lowerLimit":"6.8","upperLimit":"40.7"},{"groupId":"OG006","value":"18.2","lowerLimit":"2.3","upperLimit":"51.8"},{"groupId":"OG007","value":"11.8","lowerLimit":"1.5","upperLimit":"36.4"}]}]},{"title":"Day 84: ≥2-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"93.6","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"90.3","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"7.7"},{"groupId":"OG004","value":"53.3","lowerLimit":"26.6","upperLimit":"78.7"},{"groupId":"OG005","value":"55.2","lowerLimit":"35.7","upperLimit":"73.6"},{"groupId":"OG006","value":"53.8","lowerLimit":"25.1","upperLimit":"80.8"},{"groupId":"OG007","value":"31.6","lowerLimit":"12.6","upperLimit":"56.6"}]}]},{"title":"Day 84: ≥3-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"93.6","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"90.3","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"7.7"},{"groupId":"OG004","value":"26.7","lowerLimit":"7.8","upperLimit":"55.1"},{"groupId":"OG005","value":"27.6","lowerLimit":"12.8","upperLimit":"48.2"},{"groupId":"OG006","value":"15.4","lowerLimit":"1.9","upperLimit":"45.4"},{"groupId":"OG007","value":"26.3","lowerLimit":"9.1","upperLimit":"51.2"}]}]},{"title":"Day 84: ≥4-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"93.6","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"90.3","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"7.7"},{"groupId":"OG004","value":"26.7","lowerLimit":"7.8","upperLimit":"55.1"},{"groupId":"OG005","value":"13.8","lowerLimit":"3.9","upperLimit":"31.7"},{"groupId":"OG006","value":"15.4","lowerLimit":"1.9","upperLimit":"45.4"},{"groupId":"OG007","value":"15.8","lowerLimit":"3.4","upperLimit":"39.6"}]}]},{"title":"Day 168: ≥2-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.9","lowerLimit":"83.8","upperLimit":"NA","comment":"Greater than the highest reportable value of 99.9 due to precision"},{"groupId":"OG001","value":"97.2","lowerLimit":"85.5","upperLimit":"NA","comment":"Greater than the highest reportable value of 99.9 due to precision"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.7","upperLimit":"100.0"},{"groupId":"OG003","value":"3.1","lowerLimit":"NA","upperLimit":"16.2","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"42.9","lowerLimit":"17.7","upperLimit":"71.1"},{"groupId":"OG005","value":"26.3","lowerLimit":"9.1","upperLimit":"51.2"},{"groupId":"OG006","value":"40.0","lowerLimit":"12.2","upperLimit":"73.8"},{"groupId":"OG007","value":"30.8","lowerLimit":"9.1","upperLimit":"61.4"}]}]},{"title":"Day 168: ≥3-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.6","lowerLimit":"75.0","upperLimit":"98.0"},{"groupId":"OG001","value":"97.2","lowerLimit":"85.5","upperLimit":"NA","comment":"Greater than the highest reportable value of 99.9 due to precision"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.7","upperLimit":"100.0"},{"groupId":"OG003","value":"3.1","lowerLimit":"NA","upperLimit":"16.2","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"28.6","lowerLimit":"8.4","upperLimit":"58.1"},{"groupId":"OG005","value":"15.8","lowerLimit":"3.4","upperLimit":"39.6"},{"groupId":"OG006","value":"30.0","lowerLimit":"6.7","upperLimit":"65.2"},{"groupId":"OG007","value":"30.8","lowerLimit":"9.1","upperLimit":"61.4"}]}]},{"title":"Day 168: ≥4-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.6","lowerLimit":"75.0","upperLimit":"98.0"},{"groupId":"OG001","value":"94.4","lowerLimit":"81.3","upperLimit":"99.3"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.7","upperLimit":"100.0"},{"groupId":"OG003","value":"3.1","lowerLimit":"NA","upperLimit":"16.2","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"14.3","lowerLimit":"1.8","upperLimit":"42.8"},{"groupId":"OG005","value":"10.5","lowerLimit":"1.3","upperLimit":"33.1"},{"groupId":"OG006","value":"10.0","lowerLimit":"0.3","upperLimit":"44.5"},{"groupId":"OG007","value":"23.1","lowerLimit":"5.0","upperLimit":"53.8"}]}]},{"title":"Day 196: ≥2-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"91.2","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"9.5"},{"groupId":"OG004","value":"53.8","lowerLimit":"25.1","upperLimit":"80.8"},{"groupId":"OG005","value":"37.5","lowerLimit":"18.8","upperLimit":"59.4"},{"groupId":"OG006","value":"36.4","lowerLimit":"10.9","upperLimit":"69.2"},{"groupId":"OG007","value":"35.3","lowerLimit":"14.2","upperLimit":"61.7"}]}]},{"title":"Day 196: ≥3-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"91.2","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"9.5"},{"groupId":"OG004","value":"23.1","lowerLimit":"5.0","upperLimit":"53.8"},{"groupId":"OG005","value":"20.8","lowerLimit":"7.1","upperLimit":"42.2"},{"groupId":"OG006","value":"27.3","lowerLimit":"6.0","upperLimit":"61.0"},{"groupId":"OG007","value":"23.5","lowerLimit":"6.8","upperLimit":"49.9"}]}]},{"title":"Day 196: ≥4-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"91.2","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG003","value":"0","lowerLimit":"0.0","upperLimit":"9.5"},{"groupId":"OG004","value":"15.4","lowerLimit":"1.9","upperLimit":"45.4"},{"groupId":"OG005","value":"16.7","lowerLimit":"4.7","upperLimit":"37.4"},{"groupId":"OG006","value":"18.2","lowerLimit":"2.3","upperLimit":"51.8"},{"groupId":"OG007","value":"17.6","lowerLimit":"3.8","upperLimit":"43.4"}]}]},{"title":"Day 336: ≥2-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"91.0","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG003","value":"2.9","lowerLimit":"NA","upperLimit":"15.3","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"57.1","lowerLimit":"28.9","upperLimit":"82.3"},{"groupId":"OG005","value":"27.8","lowerLimit":"9.7","upperLimit":"53.5"},{"groupId":"OG006","value":"33.3","lowerLimit":"9.9","upperLimit":"65.1"},{"groupId":"OG007","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"}]}]},{"title":"Day 336: ≥3-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"91.0","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG003","value":"2.9","lowerLimit":"NA","upperLimit":"15.3","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"21.4","lowerLimit":"4.7","upperLimit":"50.8"},{"groupId":"OG005","value":"11.1","lowerLimit":"1.4","upperLimit":"34.7"},{"groupId":"OG006","value":"33.3","lowerLimit":"9.9","upperLimit":"65.1"},{"groupId":"OG007","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"}]}]},{"title":"Day 336: ≥4-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"91.0","upperLimit":"100.0"},{"groupId":"OG002","value":"100.0","lowerLimit":"87.2","upperLimit":"100.0"},{"groupId":"OG003","value":"2.9","lowerLimit":"NA","upperLimit":"15.3","comment":"Below the lowest reportable value of 0.1 due to precision"},{"groupId":"OG004","value":"14.3","lowerLimit":"1.8","upperLimit":"42.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"18.5"},{"groupId":"OG006","value":"33.3","lowerLimit":"9.9","upperLimit":"65.1"},{"groupId":"OG007","value":"18.8","lowerLimit":"4.0","upperLimit":"45.6"}]}]},{"title":"Day 504: ≥2-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","lowerLimit":"70.8","upperLimit":"98.9"},{"groupId":"OG001","value":"97.2","lowerLimit":"85.5","upperLimit":"NA","comment":"Greater than the highest reportable value of 99.9 due to precision"},{"groupId":"OG002","value":"100.0","lowerLimit":"85.2","upperLimit":"100.0"},{"groupId":"OG003","value":"8.3","lowerLimit":"1.8","upperLimit":"22.5"},{"groupId":"OG004","value":"42.9","lowerLimit":"17.7","upperLimit":"71.1"},{"groupId":"OG005","value":"23.5","lowerLimit":"6.8","upperLimit":"49.9"},{"groupId":"OG006","value":"27.3","lowerLimit":"6.0","upperLimit":"61.0"},{"groupId":"OG007","value":"40.0","lowerLimit":"16.3","upperLimit":"67.7"}]}]},{"title":"Day 504: ≥3-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","lowerLimit":"70.8","upperLimit":"98.9"},{"groupId":"OG001","value":"91.7","lowerLimit":"77.5","upperLimit":"98.2"},{"groupId":"OG002","value":"100.0","lowerLimit":"85.2","upperLimit":"100.0"},{"groupId":"OG003","value":"5.6","lowerLimit":"0.7","upperLimit":"18.7"},{"groupId":"OG004","value":"14.3","lowerLimit":"1.8","upperLimit":"42.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"19.5"},{"groupId":"OG006","value":"9.1","lowerLimit":"0.2","upperLimit":"41.3"},{"groupId":"OG007","value":"26.7","lowerLimit":"7.8","upperLimit":"55.1"}]}]},{"title":"Day 504: ≥4-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","lowerLimit":"70.8","upperLimit":"98.9"},{"groupId":"OG001","value":"91.7","lowerLimit":"77.5","upperLimit":"98.2"},{"groupId":"OG002","value":"100.0","lowerLimit":"85.2","upperLimit":"100.0"},{"groupId":"OG003","value":"5.6","lowerLimit":"0.7","upperLimit":"18.7"},{"groupId":"OG004","value":"14.3","lowerLimit":"1.8","upperLimit":"42.8"},{"groupId":"OG005","value":"0","lowerLimit":"0.0","upperLimit":"19.5"},{"groupId":"OG006","value":"9.1","lowerLimit":"0.2","upperLimit":"41.3"},{"groupId":"OG007","value":"20.0","lowerLimit":"4.3","upperLimit":"48.1"}]}]}]},{"type":"SECONDARY","title":"GMT of Anti-Glycoprotein B (gB)-Specific Immunoglobulin G (IgG) and Anti-Pentamer-specific IgG as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) of Post-Baseline/Baseline Titers","description":"Blood samples for antibody-mediated immunogenicity were collected during protocol-specified study visits. Serological assessment for anti-gB-specific IgG and anti-pentameric gH/gL/UL128/UL130/UL131A glycoprotein complex (Pentamer)-specific IgG binding was measured with ELISA. The GMT measures the level of inhibition of anti-gB-specific IgG (anti-gB) and anti-Pentamer-specific IgG (anti-Pentamer) against cytomegalovirus. Results are reported as fold dilution (titer). GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.","populationDescription":"Per-Protocol Set for AMI: All FAS for AMI participants who a) complied with vaccination schedule, b) complied with timings of blood sampling to have post-vaccination results available for at least 1 assay component, c) had no major protocol deviations that impacted immune response. Number Analyzed=participants evaluable at specified timepoints. Data collected based on participant serostatus and the treatment group to which the participant was randomized regardless of the part of the study.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504","groups":[{"id":"OG000","title":"Seronegative mRNA-1647 (50 ug)","description":"CMV-seronegative participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG001","title":"Seronegative mRNA-1647 (100 ug)","description":"CMV-seronegative participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG002","title":"Seronegative mRNA-1647 (150 ug)","description":"CMV-seronegative participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG003","title":"Seronegative Placebo","description":"CMV-seronegative participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."},{"id":"OG004","title":"Seropositive mRNA-1647 (50 ug)","description":"CMV-seropositive participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG005","title":"Seropositive mRNA-1647 (100 ug)","description":"CMV-seropositive participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG006","title":"Seropositive mRNA-1647 (150 ug)","description":"CMV-seropositive participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG007","title":"Seropositive Placebo","description":"CMV-seropositive participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"23"}]}],"classes":[{"title":"Baseline (Day 1): Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.50","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG001","value":"18.20","lowerLimit":"16.83","upperLimit":"19.68"},{"groupId":"OG002","value":"17.50","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG003","value":"17.50","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"1146.61","lowerLimit":"367.95","upperLimit":"3573.08"},{"groupId":"OG005","value":"2631.32","lowerLimit":"1611.38","upperLimit":"4296.84"},{"groupId":"OG006","value":"2981.12","lowerLimit":"1649.35","upperLimit":"5388.25"},{"groupId":"OG007","value":"2948.18","lowerLimit":"1683.25","upperLimit":"5163.69"}]}]},{"title":"Day 29: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.05","lowerLimit":"17.53","upperLimit":"20.70"},{"groupId":"OG001","value":"21.73","lowerLimit":"18.85","upperLimit":"25.06"},{"groupId":"OG002","value":"19.65","lowerLimit":"17.79","upperLimit":"21.71"},{"groupId":"OG003","value":"17.50","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"2121.17","lowerLimit":"645.07","upperLimit":"6974.73"},{"groupId":"OG005","value":"4849.42","lowerLimit":"2999.05","upperLimit":"7841.45"},{"groupId":"OG006","value":"6754.86","lowerLimit":"3799.57","upperLimit":"12008.74"},{"groupId":"OG007","value":"3494.48","lowerLimit":"2417.72","upperLimit":"5050.78"}]}]},{"title":"Day 56: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.82","lowerLimit":"17.18","upperLimit":"18.49"},{"groupId":"OG001","value":"24.44","lowerLimit":"19.20","upperLimit":"31.12"},{"groupId":"OG002","value":"18.53","lowerLimit":"17.06","upperLimit":"20.12"},{"groupId":"OG003","value":"19.95","lowerLimit":"15.31","upperLimit":"25.98"},{"groupId":"OG004","value":"1998.18","lowerLimit":"627.93","upperLimit":"6358.51"},{"groupId":"OG005","value":"4383.36","lowerLimit":"2308.90","upperLimit":"8321.64"},{"groupId":"OG006","value":"5908.63","lowerLimit":"3097.70","upperLimit":"11270.27"},{"groupId":"OG007","value":"4422.21","lowerLimit":"3147.66","upperLimit":"6212.85"}]}]},{"title":"Day 84: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"339.83","lowerLimit":"234.71","upperLimit":"492.04"},{"groupId":"OG001","value":"480.55","lowerLimit":"360.83","upperLimit":"639.99"},{"groupId":"OG002","value":"347.45","lowerLimit":"268.76","upperLimit":"449.18"},{"groupId":"OG003","value":"17.50","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"3699.02","lowerLimit":"2149.36","upperLimit":"6365.94"},{"groupId":"OG005","value":"4708.14","lowerLimit":"3215.43","upperLimit":"6893.83"},{"groupId":"OG006","value":"8112.05","lowerLimit":"5108.43","upperLimit":"12881.71"},{"groupId":"OG007","value":"3782.90","lowerLimit":"2685.71","upperLimit":"5328.32"}]}]},{"title":"Day 168: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.84","lowerLimit":"57.61","upperLimit":"122.00"},{"groupId":"OG001","value":"133.80","lowerLimit":"90.44","upperLimit":"197.94"},{"groupId":"OG002","value":"107.28","lowerLimit":"75.34","upperLimit":"152.76"},{"groupId":"OG003","value":"18.63","lowerLimit":"16.40","upperLimit":"21.17"},{"groupId":"OG004","value":"3384.91","lowerLimit":"1634.19","upperLimit":"7011.21"},{"groupId":"OG005","value":"5137.05","lowerLimit":"3042.33","upperLimit":"8674.05"},{"groupId":"OG006","value":"10702.55","lowerLimit":"6307.14","upperLimit":"18161.07"},{"groupId":"OG007","value":"3235.25","lowerLimit":"2174.90","upperLimit":"4812.58"}]}]},{"title":"Day 196: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1154.82","lowerLimit":"848.30","upperLimit":"1572.11"},{"groupId":"OG001","value":"962.89","lowerLimit":"680.53","upperLimit":"1362.42"},{"groupId":"OG002","value":"937.17","lowerLimit":"686.85","upperLimit":"1278.70"},{"groupId":"OG003","value":"17.50","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"4143.99","lowerLimit":"2473.48","upperLimit":"6942.73"},{"groupId":"OG005","value":"4971.82","lowerLimit":"3291.99","upperLimit":"7508.85"},{"groupId":"OG006","value":"10115.96","lowerLimit":"5983.30","upperLimit":"17103.06"},{"groupId":"OG007","value":"3274.52","lowerLimit":"2314.97","upperLimit":"4631.80"}]}]},{"title":"Day 336: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"296.60","lowerLimit":"197.73","upperLimit":"444.92"},{"groupId":"OG001","value":"396.96","lowerLimit":"269.50","upperLimit":"584.72"},{"groupId":"OG002","value":"261.98","lowerLimit":"195.16","upperLimit":"351.69"},{"groupId":"OG003","value":"20.52","lowerLimit":"14.85","upperLimit":"28.35"},{"groupId":"OG004","value":"3746.85","lowerLimit":"1860.42","upperLimit":"7546.09"},{"groupId":"OG005","value":"4130.37","lowerLimit":"2426.85","upperLimit":"7029.68"},{"groupId":"OG006","value":"8915.36","lowerLimit":"5714.18","upperLimit":"13909.90"},{"groupId":"OG007","value":"3193.29","lowerLimit":"2049.62","upperLimit":"4975.11"}]}]},{"title":"Day 504: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"170.25","lowerLimit":"103.18","upperLimit":"280.91"},{"groupId":"OG001","value":"225.31","lowerLimit":"128.30","upperLimit":"395.70"},{"groupId":"OG002","value":"156.47","lowerLimit":"107.51","upperLimit":"227.73"},{"groupId":"OG003","value":"20.62","lowerLimit":"14.78","upperLimit":"28.79"},{"groupId":"OG004","value":"2745.18","lowerLimit":"1311.43","upperLimit":"5784.14"},{"groupId":"OG005","value":"3037.74","lowerLimit":"1743.56","upperLimit":"5292.56"},{"groupId":"OG006","value":"7665.63","lowerLimit":"5045.24","upperLimit":"11646.99"},{"groupId":"OG007","value":"3491.80","lowerLimit":"2449.26","upperLimit":"4978.11"}]}]},{"title":"Baseline (Day 1): Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG001","value":"24.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG002","value":"24.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG003","value":"24.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"334.7","lowerLimit":"143.4","upperLimit":"781.2"},{"groupId":"OG005","value":"412.1","lowerLimit":"283.7","upperLimit":"598.7"},{"groupId":"OG006","value":"496.3","lowerLimit":"273.1","upperLimit":"902.2"},{"groupId":"OG007","value":"374.4","lowerLimit":"225.8","upperLimit":"620.7"}]}]},{"title":"Day 29: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"165.8","lowerLimit":"113.1","upperLimit":"243.1"},{"groupId":"OG001","value":"148.9","lowerLimit":"105.7","upperLimit":"209.6"},{"groupId":"OG002","value":"518.7","lowerLimit":"381.3","upperLimit":"705.7"},{"groupId":"OG003","value":"24.5","lowerLimit":"23.5","upperLimit":"25.6"},{"groupId":"OG004","value":"1905.20","lowerLimit":"836.5","upperLimit":"4339.2"},{"groupId":"OG005","value":"4114.8","lowerLimit":"2790.1","upperLimit":"6068.5"},{"groupId":"OG006","value":"4655.2","lowerLimit":"3036.5","upperLimit":"7136.8"},{"groupId":"OG007","value":"377.7","lowerLimit":"241.6","upperLimit":"590.5"}]}]},{"title":"Day 56: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"110.1","lowerLimit":"75.3","upperLimit":"161.0"},{"groupId":"OG001","value":"112.1","lowerLimit":"76.2","upperLimit":"164.9"},{"groupId":"OG002","value":"278.3","lowerLimit":"202.4","upperLimit":"382.5"},{"groupId":"OG003","value":"24.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"1371.3","lowerLimit":"627.0","upperLimit":"2998.9"},{"groupId":"OG005","value":"3017.4","lowerLimit":"1699.1","upperLimit":"5358.6"},{"groupId":"OG006","value":"3476.4","lowerLimit":"2259.2","upperLimit":"5349.4"},{"groupId":"OG007","value":"534.8","lowerLimit":"327.2","upperLimit":"874.2"}]}]},{"title":"Day 84: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5750.0","lowerLimit":"4006.7","upperLimit":"8251.8"},{"groupId":"OG001","value":"3165.2","lowerLimit":"2112.9","upperLimit":"4741.7"},{"groupId":"OG002","value":"5841.8","lowerLimit":"4481.9","upperLimit":"7614.3"},{"groupId":"OG003","value":"24.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"3378.1","lowerLimit":"2377.3","upperLimit":"4800.3"},{"groupId":"OG005","value":"4159.7","lowerLimit":"2770.0","upperLimit":"6246.7"},{"groupId":"OG006","value":"4556.1","lowerLimit":"3063.5","upperLimit":"6775.9"},{"groupId":"OG007","value":"469.9","lowerLimit":"294.3","upperLimit":"750.1"}]}]},{"title":"Day 168: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"573.1","lowerLimit":"387.6","upperLimit":"847.3"},{"groupId":"OG001","value":"597.0","lowerLimit":"393.9","upperLimit":"905.0"},{"groupId":"OG002","value":"661.6","lowerLimit":"468.8","upperLimit":"933.6"},{"groupId":"OG003","value":"26.2","lowerLimit":"21.9","upperLimit":"31.5"},{"groupId":"OG004","value":"2139.1","lowerLimit":"1240.2","upperLimit":"3689.7"},{"groupId":"OG005","value":"2447.0","lowerLimit":"1485.4","upperLimit":"4031.0"},{"groupId":"OG006","value":"2831.4","lowerLimit":"1932.1","upperLimit":"4149.3"},{"groupId":"OG007","value":"456.6","lowerLimit":"242.1","upperLimit":"861.4"}]}]},{"title":"Day 196: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5572.6","lowerLimit":"3871.2","upperLimit":"8021.9"},{"groupId":"OG001","value":"3709.7","lowerLimit":"2273.7","upperLimit":"6052.5"},{"groupId":"OG002","value":"6512.6","lowerLimit":"4542.7","upperLimit":"9336.7"},{"groupId":"OG003","value":"24.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"3349.3","lowerLimit":"2009.3","upperLimit":"5582.8"},{"groupId":"OG005","value":"2891.7","lowerLimit":"2014.5","upperLimit":"4150.8"},{"groupId":"OG006","value":"3239.1","lowerLimit":"2121.4","upperLimit":"4945.8"},{"groupId":"OG007","value":"369.8","lowerLimit":"220.3","upperLimit":"620.7"}]}]},{"title":"Day 336: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1230.0","lowerLimit":"810.2","upperLimit":"1867.5"},{"groupId":"OG001","value":"1623.5","lowerLimit":"1127.0","upperLimit":"2338.7"},{"groupId":"OG002","value":"1458.9","lowerLimit":"943.3","upperLimit":"2255.9"},{"groupId":"OG003","value":"28.0","lowerLimit":"20.5","upperLimit":"38.2"},{"groupId":"OG004","value":"1629.3","lowerLimit":"993.9","upperLimit":"2670.8"},{"groupId":"OG005","value":"2314.9","lowerLimit":"1364.4","upperLimit":"3927.3"},{"groupId":"OG006","value":"2177.7","lowerLimit":"1715.9","upperLimit":"2763.9"},{"groupId":"OG007","value":"508.8","lowerLimit":"262.8","upperLimit":"985.2"}]}]},{"title":"Day 504: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"508.9","lowerLimit":"313.1","upperLimit":"827.2"},{"groupId":"OG001","value":"815.9","lowerLimit":"553.1","upperLimit":"1203.6"},{"groupId":"OG002","value":"796.5","lowerLimit":"496.9","upperLimit":"1276.6"},{"groupId":"OG003","value":"27.1","lowerLimit":"21.1","upperLimit":"34.8"},{"groupId":"OG004","value":"1020.9","lowerLimit":"618.6","upperLimit":"1684.8"},{"groupId":"OG005","value":"1361.5","lowerLimit":"919.0","upperLimit":"2017.0"},{"groupId":"OG006","value":"1644.4","lowerLimit":"1232.2","upperLimit":"2194.4"},{"groupId":"OG007","value":"381.6","lowerLimit":"214.1","upperLimit":"680.2"}]}]}]},{"type":"SECONDARY","title":"GMR of Anti-gB-specific IgG and Anti-Pentamer-specific IgG as Measured by ELISA of Post-Baseline/Baseline Titers","description":"Blood samples for antibody-mediated immunogenicity were collected during protocol-specified study visits. Serological assessment for anti-gB-specific IgG and anti-Pentamer-specific IgG binding was measured with ELISA. The GMR measures the changes in immunogenicity titers within participants. Results are reported as a ratio (post-baseline/baseline titers). GMR 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation. Number Analyzed = participants who were evaluable at specified timepoints.","populationDescription":"Per-Protocol Set for AMI: All FAS for AMI participants who a) complied with vaccination schedule, b) complied with timings of blood sampling to have post-vaccination results available for at least 1 assay component, c) had no major protocol deviations that impacted immune response. Number Analyzed=participants evaluable at specified timepoints. Data collected based on participant serostatus and the treatment group to which the participant was randomized regardless of the part of the study.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504","groups":[{"id":"OG000","title":"Seronegative mRNA-1647 (50 ug)","description":"CMV-seronegative participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG001","title":"Seronegative mRNA-1647 (100 ug)","description":"CMV-seronegative participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG002","title":"Seronegative mRNA-1647 (150 ug)","description":"CMV-seronegative participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG003","title":"Seronegative Placebo","description":"CMV-seronegative participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."},{"id":"OG004","title":"Seropositive mRNA-1647 (50 ug)","description":"CMV-seropositive participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG005","title":"Seropositive mRNA-1647 (100 ug)","description":"CMV-seropositive participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG006","title":"Seropositive mRNA-1647 (150 ug)","description":"CMV-seropositive participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG007","title":"Seropositive Placebo","description":"CMV-seropositive participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"34"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"23"}]}],"classes":[{"title":"Day 29: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.088","lowerLimit":"1.002","upperLimit":"1.183"},{"groupId":"OG001","value":"1.194","lowerLimit":"1.044","upperLimit":"1.365"},{"groupId":"OG002","value":"1.123","lowerLimit":"1.016","upperLimit":"1.241"},{"groupId":"OG003","value":"1.000","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"1.850","lowerLimit":"1.283","upperLimit":"2.666"},{"groupId":"OG005","value":"1.873","lowerLimit":"1.522","upperLimit":"2.305"},{"groupId":"OG006","value":"2.128","lowerLimit":"1.529","upperLimit":"2.962"},{"groupId":"OG007","value":"1.242","lowerLimit":"0.794","upperLimit":"1.943"}]}]},{"title":"Day 56: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.018","lowerLimit":"0.981","upperLimit":"1.057"},{"groupId":"OG001","value":"1.326","lowerLimit":"1.089","upperLimit":"1.615"},{"groupId":"OG002","value":"1.059","lowerLimit":"0.975","upperLimit":"1.150"},{"groupId":"OG003","value":"1.140","lowerLimit":"0.875","upperLimit":"1.485"},{"groupId":"OG004","value":"1.743","lowerLimit":"1.243","upperLimit":"2.443"},{"groupId":"OG005","value":"1.746","lowerLimit":"1.449","upperLimit":"2.104"},{"groupId":"OG006","value":"1.954","lowerLimit":"1.349","upperLimit":"2.831"},{"groupId":"OG007","value":"1.361","lowerLimit":"0.777","upperLimit":"2.386"}]}]},{"title":"Day 84: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.419","lowerLimit":"13.412","upperLimit":"28.116"},{"groupId":"OG001","value":"26.259","lowerLimit":"19.197","upperLimit":"35.919"},{"groupId":"OG002","value":"19.854","lowerLimit":"15.357","upperLimit":"25.668"},{"groupId":"OG003","value":"1.000","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"3.226","lowerLimit":"1.552","upperLimit":"6.705"},{"groupId":"OG005","value":"1.969","lowerLimit":"1.495","upperLimit":"2.593"},{"groupId":"OG006","value":"2.863","lowerLimit":"1.877","upperLimit":"4.368"},{"groupId":"OG007","value":"1.310","lowerLimit":"0.796","upperLimit":"2.158"}]}]},{"title":"Day 168: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.791","lowerLimit":"3.292","upperLimit":"6.971"},{"groupId":"OG001","value":"7.132","lowerLimit":"4.867","upperLimit":"10.451"},{"groupId":"OG002","value":"6.130","lowerLimit":"4.305","upperLimit":"8.729"},{"groupId":"OG003","value":"1.065","lowerLimit":"0.937","upperLimit":"1.210"},{"groupId":"OG004","value":"3.397","lowerLimit":"1.441","upperLimit":"8.012"},{"groupId":"OG005","value":"1.535","lowerLimit":"1.225","upperLimit":"1.924"},{"groupId":"OG006","value":"3.408","lowerLimit":"1.578","upperLimit":"7.359"},{"groupId":"OG007","value":"1.208","lowerLimit":"0.580","upperLimit":"2.515"}]}]},{"title":"Day 196: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.990","lowerLimit":"48.474","upperLimit":"89.835"},{"groupId":"OG001","value":"51.684","lowerLimit":"33.457","upperLimit":"79.840"},{"groupId":"OG002","value":"53.552","lowerLimit":"39.249","upperLimit":"73.069"},{"groupId":"OG003","value":"1.000","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"4.210","lowerLimit":"1.489","upperLimit":"11.904"},{"groupId":"OG005","value":"1.746","lowerLimit":"1.392","upperLimit":"2.192"},{"groupId":"OG006","value":"3.466","lowerLimit":"1.748","upperLimit":"6.869"},{"groupId":"OG007","value":"1.217","lowerLimit":"0.684","upperLimit":"2.165"}]}]},{"title":"Day 336: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.949","lowerLimit":"11.299","upperLimit":"25.424"},{"groupId":"OG001","value":"21.273","lowerLimit":"13.981","upperLimit":"32.368"},{"groupId":"OG002","value":"14.971","lowerLimit":"11.152","upperLimit":"20.097"},{"groupId":"OG003","value":"1.172","lowerLimit":"0.848","upperLimit":"1.620"},{"groupId":"OG004","value":"3.761","lowerLimit":"1.475","upperLimit":"9.589"},{"groupId":"OG005","value":"1.308","lowerLimit":"0.704","upperLimit":"2.431"},{"groupId":"OG006","value":"3.009","lowerLimit":"1.740","upperLimit":"5.205"},{"groupId":"OG007","value":"1.251","lowerLimit":"0.595","upperLimit":"2.628"}]}]},{"title":"Day 504: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.728","lowerLimit":"5.896","upperLimit":"16.052"},{"groupId":"OG001","value":"12.875","lowerLimit":"7.331","upperLimit":"22.611"},{"groupId":"OG002","value":"8.941","lowerLimit":"6.144","upperLimit":"13.013"},{"groupId":"OG003","value":"1.179","lowerLimit":"0.844","upperLimit":"1.645"},{"groupId":"OG004","value":"2.764","lowerLimit":"1.171","upperLimit":"6.529"},{"groupId":"OG005","value":"1.006","lowerLimit":"0.529","upperLimit":"1.914"},{"groupId":"OG006","value":"2.535","lowerLimit":"1.370","upperLimit":"4.691"},{"groupId":"OG007","value":"1.413","lowerLimit":"0.748","upperLimit":"2.668"}]}]},{"title":"Day 29: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.91","lowerLimit":"4.71","upperLimit":"10.13"},{"groupId":"OG001","value":"6.20","lowerLimit":"4.41","upperLimit":"8.73"},{"groupId":"OG002","value":"21.61","lowerLimit":"15.89","upperLimit":"29.40"},{"groupId":"OG003","value":"1.02","lowerLimit":"0.98","upperLimit":"1.07"},{"groupId":"OG004","value":"5.69","lowerLimit":"3.32","upperLimit":"9.77"},{"groupId":"OG005","value":"10.00","lowerLimit":"6.66","upperLimit":"15.00"},{"groupId":"OG006","value":"8.01","lowerLimit":"4.19","upperLimit":"15.34"},{"groupId":"OG007","value":"1.09","lowerLimit":"0.84","upperLimit":"1.40"}]}]},{"title":"Day 56: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.59","lowerLimit":"3.14","upperLimit":"6.71"},{"groupId":"OG001","value":"4.67","lowerLimit":"3.17","upperLimit":"6.87"},{"groupId":"OG002","value":"11.59","lowerLimit":"8.43","upperLimit":"15.94"},{"groupId":"OG003","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"4.10","lowerLimit":"2.51","upperLimit":"6.69"},{"groupId":"OG005","value":"7.41","lowerLimit":"5.02","upperLimit":"10.93"},{"groupId":"OG006","value":"6.60","lowerLimit":"3.33","upperLimit":"13.07"},{"groupId":"OG007","value":"1.15","lowerLimit":"0.83","upperLimit":"1.59"}]}]},{"title":"Day 84: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"29"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"239.58","lowerLimit":"166.94","upperLimit":"343.82"},{"groupId":"OG001","value":"131.88","lowerLimit":"88.04","upperLimit":"197.57"},{"groupId":"OG002","value":"243.41","lowerLimit":"186.74","upperLimit":"317.26"},{"groupId":"OG003","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"10.09","lowerLimit":"4.21","upperLimit":"24.20"},{"groupId":"OG005","value":"9.82","lowerLimit":"6.96","upperLimit":"13.85"},{"groupId":"OG006","value":"10.21","lowerLimit":"5.09","upperLimit":"20.46"},{"groupId":"OG007","value":"1.22","lowerLimit":"0.90","upperLimit":"1.66"}]}]},{"title":"Day 168: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"32"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.88","lowerLimit":"16.15","upperLimit":"35.31"},{"groupId":"OG001","value":"24.88","lowerLimit":"16.41","upperLimit":"37.71"},{"groupId":"OG002","value":"27.56","lowerLimit":"19.53","upperLimit":"38.90"},{"groupId":"OG003","value":"1.09","lowerLimit":"0.91","upperLimit":"1.31"},{"groupId":"OG004","value":"6.24","lowerLimit":"2.46","upperLimit":"15.79"},{"groupId":"OG005","value":"4.84","lowerLimit":"3.28","upperLimit":"7.15"},{"groupId":"OG006","value":"5.39","lowerLimit":"2.32","upperLimit":"12.54"},{"groupId":"OG007","value":"0.94","lowerLimit":"0.67","upperLimit":"1.30"}]}]},{"title":"Day 196: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"37"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"24"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"232.19","lowerLimit":"161.30","upperLimit":"334.25"},{"groupId":"OG001","value":"154.57","lowerLimit":"94.74","upperLimit":"252.19"},{"groupId":"OG002","value":"271.36","lowerLimit":"189.28","upperLimit":"389.03"},{"groupId":"OG003","value":"1.00","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG004","value":"8.81","lowerLimit":"3.09","upperLimit":"25.09"},{"groupId":"OG005","value":"6.30","lowerLimit":"4.50","upperLimit":"8.81"},{"groupId":"OG006","value":"6.84","lowerLimit":"3.66","upperLimit":"12.79"},{"groupId":"OG007","value":"0.99","lowerLimit":"0.74","upperLimit":"1.31"}]}]},{"title":"Day 336: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.25","lowerLimit":"33.76","upperLimit":"77.81"},{"groupId":"OG001","value":"67.64","lowerLimit":"46.96","upperLimit":"97.45"},{"groupId":"OG002","value":"60.79","lowerLimit":"39.31","upperLimit":"93.99"},{"groupId":"OG003","value":"1.17","lowerLimit":"0.85","upperLimit":"1.59"},{"groupId":"OG004","value":"4.75","lowerLimit":"2.05","upperLimit":"11.01"},{"groupId":"OG005","value":"4.97","lowerLimit":"2.84","upperLimit":"8.96"},{"groupId":"OG006","value":"4.43","lowerLimit":"2.39","upperLimit":"8.23"},{"groupId":"OG007","value":"1.38","lowerLimit":"0.85","upperLimit":"2.26"}]}]},{"title":"Day 504: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"36"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.20","lowerLimit":"13.04","upperLimit":"34.47"},{"groupId":"OG001","value":"34.00","lowerLimit":"23.05","upperLimit":"50.15"},{"groupId":"OG002","value":"33.19","lowerLimit":"20.70","upperLimit":"53.19"},{"groupId":"OG003","value":"1.13","lowerLimit":"0.88","upperLimit":"1.45"},{"groupId":"OG004","value":"2.98","lowerLimit":"1.47","upperLimit":"6.02"},{"groupId":"OG005","value":"2.86","lowerLimit":"1.83","upperLimit":"4.48"},{"groupId":"OG006","value":"3.12","lowerLimit":"1.59","upperLimit":"6.12"},{"groupId":"OG007","value":"1.08","lowerLimit":"0.73","upperLimit":"1.60"}]}]}]},{"type":"SECONDARY","title":"GMT of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection at Each Timepoint, in the CMV-Seropositive Group and in the CMV-Seronegative Group","description":"Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits. Serological assessment of serum anti-CMV nAb titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay. Results are reported as fold dilution (titer). GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.","populationDescription":"Per-Protocol Set for AMI: All FAS for AMI participants who a) complied with vaccination schedule, b) complied with timings of blood sampling to have post-vaccination results available for at least 1 assay component, c) had no major protocol deviations that impacted immune response. Number Analyzed=participants evaluable at specified timepoints. Data collected based on participant serostatus and the treatment group to which the participant was randomized regardless of the part of the study.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504","groups":[{"id":"OG000","title":"Seronegative mRNA-1647 - Total","description":"CMV-seronegative participants received mRNA-1647 (50, 100, and 150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG001","title":"Seropositive mRNA-1647 - Total","description":"CMV-seropositive participants received mRNA-1647 (50, 100, and 150 ug) by IM injection on Day 1, Day 56, and Day 168."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Baseline (Day 1): Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"8","upperLimit":"8"},{"groupId":"OG001","value":"4320.2","lowerLimit":"2826.0","upperLimit":"6604.4"}]}]},{"title":"Day 29: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1831.4","lowerLimit":"1389.5","upperLimit":"2414.0"},{"groupId":"OG001","value":"63523.6","lowerLimit":"41451.0","upperLimit":"97350.0"}]}]},{"title":"Day 56: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1012.5","lowerLimit":"771.5","upperLimit":"1328.7"},{"groupId":"OG001","value":"49108.9","lowerLimit":"29931.2","upperLimit":"80574.4"}]}]},{"title":"Day 84: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49657.3","lowerLimit":"40590.4","upperLimit":"60749.5"},{"groupId":"OG001","value":"96749.5","lowerLimit":"73584.9","upperLimit":"127206.3"}]}]},{"title":"Day 168: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9491.4","lowerLimit":"7416.5","upperLimit":"12146.6"},{"groupId":"OG001","value":"51869.1","lowerLimit":"37732.0","upperLimit":"71302.9"}]}]},{"title":"Day 196: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"119972.6","lowerLimit":"97209.9","upperLimit":"148065.5"},{"groupId":"OG001","value":"90790.0","lowerLimit":"66884.6","upperLimit":"123239.5"}]}]},{"title":"Day 336: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21792.6","lowerLimit":"17628.4","upperLimit":"26940.5"},{"groupId":"OG001","value":"38677.5","lowerLimit":"29211.0","upperLimit":"51211.9"}]}]},{"title":"Day 504: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12230.4","lowerLimit":"9633.5","upperLimit":"15527.2"},{"groupId":"OG001","value":"26187.0","lowerLimit":"19029.4","upperLimit":"36036.8"}]}]},{"title":"Baseline (Day 1): Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG001","value":"4421.5","lowerLimit":"2902.5","upperLimit":"6735.4"}]}]},{"title":"Day 29: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"114.7","lowerLimit":"86.1","upperLimit":"152.7"},{"groupId":"OG001","value":"10857.7","lowerLimit":"7600.8","upperLimit":"15510.2"}]}]},{"title":"Day 56: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.5","lowerLimit":"44.4","upperLimit":"82.3"},{"groupId":"OG001","value":"8615.0","lowerLimit":"5603.4","upperLimit":"13245.1"}]}]},{"title":"Day 84: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4252.5","lowerLimit":"3634.6","upperLimit":"4974.1"},{"groupId":"OG001","value":"10775.2","lowerLimit":"8944.2","upperLimit":"12981.0"}]}]},{"title":"Day 168: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"467.1","lowerLimit":"363.4","upperLimit":"600.3"},{"groupId":"OG001","value":"10226.2","lowerLimit":"7702.8","upperLimit":"13576.2"}]}]},{"title":"Day 196: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3460.1","lowerLimit":"2941.4","upperLimit":"4070.3"},{"groupId":"OG001","value":"9909.0","lowerLimit":"7954.2","upperLimit":"12344.1"}]}]},{"title":"Day 336: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1153.8","lowerLimit":"919.1","upperLimit":"1448.4"},{"groupId":"OG001","value":"9373.9","lowerLimit":"7269.0","upperLimit":"12088.3"}]}]},{"title":"Day 504: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"610.5","lowerLimit":"447.6","upperLimit":"832.6"},{"groupId":"OG001","value":"7860.4","lowerLimit":"5883.2","upperLimit":"10502.2"}]}]}]},{"type":"SECONDARY","title":"GMR of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection at Each Timepoint, in the CMV-Seropositive Group and in the CMV-Seronegative Group","description":"Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits. Serological assessment of serum anti-CMV nAb titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay. The GMR measures the changes in immunogenicity titers within participants. Results are reported as a ratio (post-baseline/baseline titers). GMR 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.","populationDescription":"Per-Protocol Set for AMI: All FAS for AMI participants who a) complied with vaccination schedule, b) complied with timings of blood sampling to have post-vaccination results available for at least 1 assay component, c) had no major protocol deviations that impacted immune response. Number Analyzed=participants evaluable at specified timepoints. Data collected based on participant serostatus and the treatment group to which the participant was randomized regardless of the part of the study.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504","groups":[{"id":"OG000","title":"Seronegative mRNA-1647 - Total","description":"CMV-seronegative participants received mRNA-1647 (50, 100, and 150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG001","title":"Seropositive mRNA-1647 - Total","description":"CMV-seropositive participants received mRNA-1647 (50, 100, and 150 ug) by IM injection on Day 1, Day 56, and Day 168."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Day 29: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"228.93","lowerLimit":"173.68","upperLimit":"301.75"},{"groupId":"OG001","value":"14.76","lowerLimit":"10.42","upperLimit":"20.91"}]}]},{"title":"Day 56: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"126.56","lowerLimit":"96.43","upperLimit":"166.09"},{"groupId":"OG001","value":"13.63","lowerLimit":"9.64","upperLimit":"19.29"}]}]},{"title":"Day 84: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6207.16","lowerLimit":"5073.80","upperLimit":"7593.69"},{"groupId":"OG001","value":"25.47","lowerLimit":"16.56","upperLimit":"39.18"}]}]},{"title":"Day 168: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1186.42","lowerLimit":"927.07","upperLimit":"1518.32"},{"groupId":"OG001","value":"12.61","lowerLimit":"7.70","upperLimit":"20.65"}]}]},{"title":"Day 196: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14996.58","lowerLimit":"12151.23","upperLimit":"18508.18"},{"groupId":"OG001","value":"20.73","lowerLimit":"12.44","upperLimit":"34.53"}]}]},{"title":"Day 336: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2724.07","lowerLimit":"2203.55","upperLimit":"3367.56"},{"groupId":"OG001","value":"8.86","lowerLimit":"5.39","upperLimit":"14.56"}]}]},{"title":"Day 504: Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1528.80","lowerLimit":"1204.19","upperLimit":"1940.90"},{"groupId":"OG001","value":"6.40","lowerLimit":"3.92","upperLimit":"10.44"}]}]},{"title":"Day 29: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.33","lowerLimit":"10.76","upperLimit":"19.08"},{"groupId":"OG001","value":"2.47","lowerLimit":"2.00","upperLimit":"3.05"}]}]},{"title":"Day 56: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.56","lowerLimit":"5.55","upperLimit":"10.29"},{"groupId":"OG001","value":"2.04","lowerLimit":"1.66","upperLimit":"2.49"}]}]},{"title":"Day 84: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"531.57","lowerLimit":"454.45","upperLimit":"621.77"},{"groupId":"OG001","value":"2.58","lowerLimit":"1.81","upperLimit":"3.67"}]}]},{"title":"Day 168: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.39","lowerLimit":"45.43","upperLimit":"75.04"},{"groupId":"OG001","value":"2.23","lowerLimit":"1.46","upperLimit":"3.40"}]}]},{"title":"Day 196: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"432.51","lowerLimit":"367.67","upperLimit":"508.79"},{"groupId":"OG001","value":"2.24","lowerLimit":"1.49","upperLimit":"3.37"}]}]},{"title":"Day 336: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"144.22","lowerLimit":"114.88","upperLimit":"181.05"},{"groupId":"OG001","value":"2.14","lowerLimit":"1.40","upperLimit":"3.27"}]}]},{"title":"Day 504: Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76.31","lowerLimit":"55.95","upperLimit":"104.08"},{"groupId":"OG001","value":"1.77","lowerLimit":"1.17","upperLimit":"5.70"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With ≥2-Fold, 3-Fold, and 4-Fold Increases Over Baseline of Serum nAb Against Epithelial Cell Infection and Against Fibroblast Infection in the CMV-Seropositive and CMV-Seronegative Groups","description":"Blood samples for antibody-mediated immunogenicity analysis were collected during protocol-specified study visits. Serological assessment of serum anti-CMV nAb titers against epithelial cell infection and fibroblast infection were measured by a neutralization assay. A ≥z-fold increase from baseline at participant level was defined as a ≥z \\* the LLOQ for participants with baseline antibody level below the LLOQ, or a z-times or higher-level ratio in participants with baseline antibody level equal to or above the LLOQ. LLOQ=16. Results are reported as percentage of participants with ≥2-fold, 3-fold, and 4-fold increases in serum anti-CMV nAb titers from baseline. 95% CI for percentage is calculated using the Clopper-Pearson method.","populationDescription":"Per-Protocol Set for AMI: All FAS for AMI participants who a) complied with vaccination schedule, b) complied with timings of blood sampling to have post-vaccination results available for at least 1 assay component, c) had no major protocol deviations that impacted immune response. Number Analyzed=participants evaluable at specified timepoints. Data collected based on participant serostatus and the treatment group to which the participant was randomized regardless of the part of the study.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504","groups":[{"id":"OG000","title":"Seronegative mRNA-1647 - Total","description":"CMV-seronegative participants received mRNA-1647 (50, 100, and 150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG001","title":"Seropositive mRNA-1647 - Total","description":"CMV-seropositive participants received mRNA-1647 (50, 100, and 150 ug) by IM injection on Day 1, Day 56, and Day 168."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Day 29: ≥2-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","lowerLimit":"91.3","upperLimit":"98.5"},{"groupId":"OG001","value":"93.4","lowerLimit":"84.1","upperLimit":"98.2"}]}]},{"title":"Day 29: ≥3-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","lowerLimit":"90.4","upperLimit":"98.1"},{"groupId":"OG001","value":"88.5","lowerLimit":"77.8","upperLimit":"95.3"}]}]},{"title":"Day 29: ≥4-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","lowerLimit":"90.4","upperLimit":"98.1"},{"groupId":"OG001","value":"85.2","lowerLimit":"73.8","upperLimit":"93.0"}]}]},{"title":"Day 56: ≥2-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.7","lowerLimit":"91.8","upperLimit":"99.1"},{"groupId":"OG001","value":"96.1","lowerLimit":"86.5","upperLimit":"99.5"}]}]},{"title":"Day 56: ≥3-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.0","lowerLimit":"89.5","upperLimit":"98.2"},{"groupId":"OG001","value":"90.2","lowerLimit":"78.6","upperLimit":"96.7"}]}]},{"title":"Day 56: ≥4-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.4","lowerLimit":"87.4","upperLimit":"97.1"},{"groupId":"OG001","value":"84.3","lowerLimit":"71.4","upperLimit":"93.0"}]}]},{"title":"Day 84: ≥2-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.9","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"93.7","upperLimit":"100.0"}]}]},{"title":"Day 84: ≥3-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.9","upperLimit":"100.0"},{"groupId":"OG001","value":"100.0","lowerLimit":"93.7","upperLimit":"100.0"}]}]},{"title":"Day 84: ≥4-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.9","upperLimit":"100.0"},{"groupId":"OG001","value":"96.5","lowerLimit":"87.9","upperLimit":"99.6"}]}]},{"title":"Day 168: ≥2-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","lowerLimit":"94.3","upperLimit":"NA","comment":"Greater than the highest reportable value of 99.9 due to precision"},{"groupId":"OG001","value":"97.7","lowerLimit":"87.7","upperLimit":"NA","comment":"Greater than the highest reportable value of 99.9 due to precision"}]}]},{"title":"Day 168: ≥3-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","lowerLimit":"94.3","upperLimit":"NA","comment":"Greater than the highest reportable value of 99.9 due to precision"},{"groupId":"OG001","value":"83.7","lowerLimit":"69.3","upperLimit":"93.2"}]}]},{"title":"Day 168: ≥4-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","lowerLimit":"94.3","upperLimit":"NA","comment":"Greater than the highest reportable value of 99.9 due to precision"},{"groupId":"OG001","value":"76.7","lowerLimit":"61.4","upperLimit":"88.2"}]}]},{"title":"Day 196: ≥2-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.2","upperLimit":"100.0"},{"groupId":"OG001","value":"97.9","lowerLimit":"88.9","upperLimit":"NA","comment":"Greater than the highest reportable value of 99.9 due to precision"}]}]},{"title":"Day 196: ≥3-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.2","upperLimit":"100.0"},{"groupId":"OG001","value":"93.8","lowerLimit":"82.8","upperLimit":"98.7"}]}]},{"title":"Day 196: ≥4-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.2","upperLimit":"100.0"},{"groupId":"OG001","value":"87.5","lowerLimit":"74.8","upperLimit":"95.3"}]}]},{"title":"Day 336: ≥2-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.1","upperLimit":"100.0"},{"groupId":"OG001","value":"86.4","lowerLimit":"72.6","upperLimit":"94.8"}]}]},{"title":"Day 336: ≥3-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.1","upperLimit":"100.0"},{"groupId":"OG001","value":"75.0","lowerLimit":"59.7","upperLimit":"86.8"}]}]},{"title":"Day 336: ≥4-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.1","upperLimit":"100.0"},{"groupId":"OG001","value":"70.5","lowerLimit":"54.8","upperLimit":"83.2"}]}]},{"title":"Day 504: ≥2-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"95.5","upperLimit":"100.0"},{"groupId":"OG001","value":"78.6","lowerLimit":"63.2","upperLimit":"89.7"}]}]},{"title":"Day 504: ≥3-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"95.5","upperLimit":"100.0"},{"groupId":"OG001","value":"69.0","lowerLimit":"52.9","upperLimit":"82.4"}]}]},{"title":"Day 504: ≥4-Fold Increase - Epithelial Cell","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"95.5","upperLimit":"100.0"},{"groupId":"OG001","value":"54.8","lowerLimit":"38.7","upperLimit":"70.2"}]}]},{"title":"Day 29: ≥2-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.4","lowerLimit":"69.7","upperLimit":"83.9"},{"groupId":"OG001","value":"54.1","lowerLimit":"40.8","upperLimit":"66.9"}]}]},{"title":"Day 29: ≥3-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.6","lowerLimit":"64.6","upperLimit":"79.7"},{"groupId":"OG001","value":"31.1","lowerLimit":"19.9","upperLimit":"44.3"}]}]},{"title":"Day 29: ≥4-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.8","lowerLimit":"59.6","upperLimit":"75.3"},{"groupId":"OG001","value":"19.7","lowerLimit":"10.6","upperLimit":"31.8"}]}]},{"title":"Day 56: ≥2-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","lowerLimit":"55.2","upperLimit":"73.0"},{"groupId":"OG001","value":"35.3","lowerLimit":"22.4","upperLimit":"49.9"}]}]},{"title":"Day 56: ≥3-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.7","lowerLimit":"49.4","upperLimit":"67.6"},{"groupId":"OG001","value":"29.4","lowerLimit":"17.5","upperLimit":"43.8"}]}]},{"title":"Day 56: ≥4-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51.2","lowerLimit":"42.0","upperLimit":"60.4"},{"groupId":"OG001","value":"19.6","lowerLimit":"9.8","upperLimit":"33.1"}]}]},{"title":"Day 84: ≥2-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.9","upperLimit":"100.0"},{"groupId":"OG001","value":"54.4","lowerLimit":"40.7","upperLimit":"67.6"}]}]},{"title":"Day 84: ≥3-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.9","upperLimit":"100.0"},{"groupId":"OG001","value":"24.6","lowerLimit":"14.1","upperLimit":"37.8"}]}]},{"title":"Day 84: ≥4-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.9","upperLimit":"100.0"},{"groupId":"OG001","value":"17.5","lowerLimit":"8.7","upperLimit":"29.9"}]}]},{"title":"Day 168: ≥2-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","lowerLimit":"92.7","upperLimit":"99.7"},{"groupId":"OG001","value":"34.9","lowerLimit":"21.0","upperLimit":"50.9"}]}]},{"title":"Day 168: ≥3-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","lowerLimit":"89.7","upperLimit":"98.9"},{"groupId":"OG001","value":"23.3","lowerLimit":"11.8","upperLimit":"38.6"}]}]},{"title":"Day 168: ≥4-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.8","lowerLimit":"88.3","upperLimit":"98.3"},{"groupId":"OG001","value":"11.6","lowerLimit":"3.9","upperLimit":"25.1"}]}]},{"title":"Day 196: ≥2-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.2","upperLimit":"100.0"},{"groupId":"OG001","value":"41.7","lowerLimit":"27.6","upperLimit":"56.8"}]}]},{"title":"Day 196: ≥3-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.2","upperLimit":"100.0"},{"groupId":"OG001","value":"22.9","lowerLimit":"12.0","upperLimit":"37.3"}]}]},{"title":"Day 196: ≥4-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.2","upperLimit":"100.0"},{"groupId":"OG001","value":"16.7","lowerLimit":"7.5","upperLimit":"30.2"}]}]},{"title":"Day 336: ≥2-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.1","upperLimit":"100.0"},{"groupId":"OG001","value":"38.6","lowerLimit":"24.4","upperLimit":"54.5"}]}]},{"title":"Day 336: ≥3-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.1","upperLimit":"100.0"},{"groupId":"OG001","value":"20.5","lowerLimit":"9.8","upperLimit":"35.3"}]}]},{"title":"Day 336: ≥4-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","lowerLimit":"96.1","upperLimit":"100.0"},{"groupId":"OG001","value":"13.6","lowerLimit":"5.2","upperLimit":"27.4"}]}]},{"title":"Day 504: ≥2-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.3","lowerLimit":"89.6","upperLimit":"99.2"},{"groupId":"OG001","value":"31.0","lowerLimit":"17.6","upperLimit":"47.1"}]}]},{"title":"Day 504: ≥3-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","lowerLimit":"86.2","upperLimit":"98.0"},{"groupId":"OG001","value":"7.1","lowerLimit":"1.5","upperLimit":"19.5"}]}]},{"title":"Day 504: ≥4-Fold Increase - Fibroblast","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","lowerLimit":"86.2","upperLimit":"98.0"},{"groupId":"OG001","value":"7.1","lowerLimit":"1.5","upperLimit":"19.5"}]}]}]},{"type":"SECONDARY","title":"GMT of Antigen-Specific IgG (ELISA) at Each Timepoint in the CMV-Seropositive and CMV-Seronegative Groups","description":"Blood samples for antibody-mediated immunogenicity were collected during protocol-specified study visits. Serological assessment for anti-gB-specific IgG and anti-Pentamer-specific IgG binding was measured with ELISA. Results are reported as fold dilution (titer). GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.","populationDescription":"Per-Protocol Set for AMI: All FAS for AMI participants who a) complied with vaccination schedule, b) complied with timings of blood sampling to have post-vaccination results available for at least 1 assay component, c) had no major protocol deviations that impacted immune response. Number Analyzed=participants evaluable at specified timepoints. Data collected based on participant serostatus and the treatment group to which the participant was randomized regardless of the part of the study.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Baseline (Day 1), Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504","groups":[{"id":"OG000","title":"Seronegative mRNA-1647 - Total","description":"CMV-seronegative participants received mRNA-1647 (50, 100, and 150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG001","title":"Seropositive mRNA-1647 - Total","description":"CMV-seropositive participants received mRNA-1647 (50, 100, and 150 ug) by IM injection on Day 1, Day 56, and Day 168."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Baseline (Day 1): Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.79","lowerLimit":"17.22","upperLimit":"18.38"},{"groupId":"OG001","value":"2230.11","lowerLimit":"1518.78","upperLimit":"3274.58"}]}]},{"title":"Day 29: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.35","lowerLimit":"18.94","upperLimit":"21.85"},{"groupId":"OG001","value":"4246.74","lowerLimit":"2852.16","upperLimit":"6323.21"}]}]},{"title":"Day 56: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.43","lowerLimit":"18.47","upperLimit":"22.59"},{"groupId":"OG001","value":"3710.50","lowerLimit":"2328.94","upperLimit":"5911.61"}]}]},{"title":"Day 84: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"402.71","lowerLimit":"338.18","upperLimit":"479.54"},{"groupId":"OG001","value":"5002.29","lowerLimit":"3862.97","upperLimit":"6477.63"}]}]},{"title":"Day 168: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"107.35","lowerLimit":"86.61","upperLimit":"133.05"},{"groupId":"OG001","value":"5319.40","lowerLimit":"3744.81","upperLimit":"7556.07"}]}]},{"title":"Day 196: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1006.64","lowerLimit":"833.96","upperLimit":"1215.07"},{"groupId":"OG001","value":"5569.16","lowerLimit":"4230.24","upperLimit":"7331.86"}]}]},{"title":"Day 336: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"323.30","lowerLimit":"261.11","upperLimit":"400.30"},{"groupId":"OG001","value":"4939.18","lowerLimit":"3561.20","upperLimit":"6850.36"}]}]},{"title":"Day 504: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"188.26","lowerLimit":"140.15","upperLimit":"252.89"},{"groupId":"OG001","value":"3746.71","lowerLimit":"2640.32","upperLimit":"5316.70"}]}]},{"title":"Baseline (Day 1): Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","lowerLimit":"NA","upperLimit":"NA","comment":"Not estimable as all individual values were identical."},{"groupId":"OG001","value":"410.0","lowerLimit":"305.1","upperLimit":"550.8"}]}]},{"title":"Day 29: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"212.8","lowerLimit":"171.0","upperLimit":"264.9"},{"groupId":"OG001","value":"3495.7","lowerLimit":"2587.4","upperLimit":"4723.0"}]}]},{"title":"Day 56: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"145.0","lowerLimit":"116.1","upperLimit":"181.0"},{"groupId":"OG001","value":"2466.9","lowerLimit":"1705.9","upperLimit":"3567.5"}]}]},{"title":"Day 84: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4362.6","lowerLimit":"3487.8","upperLimit":"5456.6"},{"groupId":"OG001","value":"4020.6","lowerLimit":"3182.2","upperLimit":"5079.9"}]}]},{"title":"Day 168: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"606.9","lowerLimit":"487.5","upperLimit":"755.4"},{"groupId":"OG001","value":"2423.0","lowerLimit":"1837.5","upperLimit":"3195.1"}]}]},{"title":"Day 196: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4901.2","lowerLimit":"3809.7","upperLimit":"6305.5"},{"groupId":"OG001","value":"3088.3","lowerLimit":"2452.5","upperLimit":"3888.9"}]}]},{"title":"Day 336: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1452.0","lowerLimit":"1159.3","upperLimit":"1818.7"},{"groupId":"OG001","value":"2035.9","lowerLimit":"1570.6","upperLimit":"2369.1"}]}]},{"title":"Day 504: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"712.8","lowerLimit":"556.0","upperLimit":"913.9"},{"groupId":"OG001","value":"1299.6","lowerLimit":"1032.0","upperLimit":"1636.6"}]}]}]},{"type":"SECONDARY","title":"GMR of Antigen-Specific IgG (ELISA) at Each Timepoint in the CMV-Seropositive and CMV-Seronegative Groups","description":"Blood samples for antibody-mediated immunogenicity were collected during protocol-specified study visits. Serological assessment for anti-gB-specific IgG and anti-Pentamer-specific IgG binding was measured with ELISA. The GMR measures the changes in immunogenicity titers within participants. Results are reported as a ratio (post-baseline/baseline titers). GMR 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.","populationDescription":"Per-Protocol Set for AMI: All FAS for AMI participants who a) complied with vaccination schedule, b) complied with timings of blood sampling to have post-vaccination results available for at least 1 assay component, c) had no major protocol deviations that impacted immune response. Number Analyzed=participants evaluable at specified timepoints. Data collected based on participant serostatus and the treatment group to which the participant was randomized regardless of the part of the study.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Day 29, Day 56, Day 84, Day 168, Day 196, Day 336, Day 504","groups":[{"id":"OG000","title":"Seronegative mRNA-1647 - Total","description":"CMV-seronegative participants received mRNA-1647 (50, 100, and 150 ug) by IM injection on Day 1, Day 56, and Day 168."},{"id":"OG001","title":"Seropositive mRNA-1647 - Total","description":"CMV-seropositive participants received mRNA-1647 (50, 100, and 150 ug) by IM injection on Day 1, Day 56, and Day 168."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"64"}]}],"classes":[{"title":"Day 29: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.143","lowerLimit":"1.068","upperLimit":"1.223"},{"groupId":"OG001","value":"1.919","lowerLimit":"1.650","upperLimit":"2.231"}]}]},{"title":"Day 56: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.144","lowerLimit":"1.052","upperLimit":"1.243"},{"groupId":"OG001","value":"1.788","lowerLimit":"1.547","upperLimit":"2.067"}]}]},{"title":"Day 84: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.533","lowerLimit":"18.754","upperLimit":"27.073"},{"groupId":"OG001","value":"2.442","lowerLimit":"1.1911","upperLimit":"3.120"}]}]},{"title":"Day 168: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.976","lowerLimit":"4.838","upperLimit":"7.383"},{"groupId":"OG001","value":"2.393","lowerLimit":"1.712","upperLimit":"3.346"}]}]},{"title":"Day 196: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.010","lowerLimit":"45.056","upperLimit":"69.628"},{"groupId":"OG001","value":"2.593","lowerLimit":"1.867","upperLimit":"3.603"}]}]},{"title":"Day 336: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.984","lowerLimit":"14.394","upperLimit":"22.469"},{"groupId":"OG001","value":"2.297","lowerLimit":"1.523","upperLimit":"3.467"}]}]},{"title":"Day 504: Anti-gB","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.758","lowerLimit":"8.009","upperLimit":"14.451"},{"groupId":"OG001","value":"1.795","lowerLimit":"1.188","upperLimit":"2.712"}]}]},{"title":"Day 29: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.87","lowerLimit":"7.12","upperLimit":"11.04"},{"groupId":"OG001","value":"8.30","lowerLimit":"6.27","upperLimit":"11.00"}]}]},{"title":"Day 56: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.04","lowerLimit":"4.84","upperLimit":"7.54"},{"groupId":"OG001","value":"6.07","lowerLimit":"4.63","upperLimit":"7.95"}]}]},{"title":"Day 84: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"57"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"181.77","lowerLimit":"145.33","upperLimit":"227.36"},{"groupId":"OG001","value":"9.98","lowerLimit":"7.36","upperLimit":"13.53"}]}]},{"title":"Day 168: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.29","lowerLimit":"20.31","upperLimit":"31.48"},{"groupId":"OG001","value":"5.39","lowerLimit":"3.75","upperLimit":"7.75"}]}]},{"title":"Day 196: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"204.22","lowerLimit":"158.74","upperLimit":"262.73"},{"groupId":"OG001","value":"7.03","lowerLimit":"5.06","upperLimit":"9.76"}]}]},{"title":"Day 336: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.50","lowerLimit":"48.30","upperLimit":"75.78"},{"groupId":"OG001","value":"4.75","lowerLimit":"3.32","upperLimit":"6.79"}]}]},{"title":"Day 504: Anti-Pentamer","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.70","lowerLimit":"23.17","upperLimit":"38.08"},{"groupId":"OG001","value":"2.97","lowerLimit":"2.17","upperLimit":"4.06"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"18 months","description":"Adverse events and all-cause mortality based upon the Safety Set: all randomized participants who received any study vaccination. Safety data were collected based on the treatment a participant received, regardless of the part of the study.","eventGroups":[{"id":"EG000","title":"Seronegative mRNA-1647 (50 ug)","description":"CMV-seronegative participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168.","deathsNumAffected":0,"deathsNumAtRisk":45,"seriousNumAffected":0,"seriousNumAtRisk":45,"otherNumAffected":40,"otherNumAtRisk":45},{"id":"EG001","title":"Seronegative mRNA-1647 (100 ug)","description":"CMV-seronegative participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168.","deathsNumAffected":0,"deathsNumAtRisk":72,"seriousNumAffected":1,"seriousNumAtRisk":72,"otherNumAffected":67,"otherNumAtRisk":72},{"id":"EG002","title":"Seronegative mRNA-1647 (150 ug)","description":"CMV-seronegative participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168.","deathsNumAffected":0,"deathsNumAtRisk":45,"seriousNumAffected":0,"seriousNumAtRisk":45,"otherNumAffected":44,"otherNumAtRisk":45},{"id":"EG003","title":"Seronegative Placebo","description":"CMV-seronegative participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168.","deathsNumAffected":0,"deathsNumAtRisk":53,"seriousNumAffected":0,"seriousNumAtRisk":53,"otherNumAffected":38,"otherNumAtRisk":53},{"id":"EG004","title":"Seropositive mRNA-1647 (50 ug)","description":"CMV-seropositive participants received mRNA-1647 (50 ug) by IM injection on Day 1, Day 56, and Day 168.","deathsNumAffected":0,"deathsNumAtRisk":18,"seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":18,"otherNumAtRisk":18},{"id":"EG005","title":"Seropositive mRNA-1647 (100 ug)","description":"CMV-seropositive participants received mRNA-1647 (100 ug) by IM injection on Day 1, Day 56, and Day 168.","deathsNumAffected":0,"deathsNumAtRisk":37,"seriousNumAffected":1,"seriousNumAtRisk":37,"otherNumAffected":36,"otherNumAtRisk":37},{"id":"EG006","title":"Seropositive mRNA-1647 (150 ug)","description":"CMV-seropositive participants received mRNA-1647 (150 ug) by IM injection on Day 1, Day 56, and Day 168.","deathsNumAffected":0,"deathsNumAtRisk":18,"seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":18,"otherNumAtRisk":18},{"id":"EG007","title":"Seropositive Placebo","description":"CMV-seropositive participants received a placebo-matching IM injection on Day 1, Day 56, and Day 168.","deathsNumAffected":0,"deathsNumAtRisk":27,"seriousNumAffected":0,"seriousNumAtRisk":27,"otherNumAffected":20,"otherNumAtRisk":27}],"seriousEvents":[{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"At the time of assessment, the investigator determined this Anxiety was not related to the investigational product and the event resolved.","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"At the time of assessment, the investigator determined this Depression was not related to the investigational product and the event resolved.","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Follicular thyroid cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"At the time of assessment, the investigator determined this Follicular thyroid cancer was not related to the investigational product and the event resolved.","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":1,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]}],"otherEvents":[{"term":"Ear discomfort","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":1,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Abdominal tenderness","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":1,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":1,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":45},{"groupId":"EG001","numAffected":24,"numAtRisk":72},{"groupId":"EG002","numAffected":15,"numAtRisk":45},{"groupId":"EG003","numAffected":5,"numAtRisk":53},{"groupId":"EG004","numAffected":7,"numAtRisk":18},{"groupId":"EG005","numAffected":17,"numAtRisk":37},{"groupId":"EG006","numAffected":8,"numAtRisk":18},{"groupId":"EG007","numAffected":4,"numAtRisk":27}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":45},{"groupId":"EG001","numAffected":39,"numAtRisk":72},{"groupId":"EG002","numAffected":28,"numAtRisk":45},{"groupId":"EG003","numAffected":8,"numAtRisk":53},{"groupId":"EG004","numAffected":10,"numAtRisk":18},{"groupId":"EG005","numAffected":25,"numAtRisk":37},{"groupId":"EG006","numAffected":13,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":45},{"groupId":"EG001","numAffected":50,"numAtRisk":72},{"groupId":"EG002","numAffected":37,"numAtRisk":45},{"groupId":"EG003","numAffected":24,"numAtRisk":53},{"groupId":"EG004","numAffected":17,"numAtRisk":18},{"groupId":"EG005","numAffected":28,"numAtRisk":37},{"groupId":"EG006","numAffected":15,"numAtRisk":18},{"groupId":"EG007","numAffected":9,"numAtRisk":27}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":45},{"groupId":"EG001","numAffected":13,"numAtRisk":72},{"groupId":"EG002","numAffected":13,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":1,"numAtRisk":18},{"groupId":"EG005","numAffected":4,"numAtRisk":37},{"groupId":"EG006","numAffected":2,"numAtRisk":18},{"groupId":"EG007","numAffected":1,"numAtRisk":27}]},{"term":"Injection site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":45},{"groupId":"EG001","numAffected":13,"numAtRisk":72},{"groupId":"EG002","numAffected":14,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":3,"numAtRisk":18},{"groupId":"EG005","numAffected":6,"numAtRisk":37},{"groupId":"EG006","numAffected":2,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Injection site lymphadenopathy","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":45},{"groupId":"EG001","numAffected":27,"numAtRisk":72},{"groupId":"EG002","numAffected":16,"numAtRisk":45},{"groupId":"EG003","numAffected":6,"numAtRisk":53},{"groupId":"EG004","numAffected":6,"numAtRisk":18},{"groupId":"EG005","numAffected":16,"numAtRisk":37},{"groupId":"EG006","numAffected":8,"numAtRisk":18},{"groupId":"EG007","numAffected":3,"numAtRisk":27}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":45},{"groupId":"EG001","numAffected":62,"numAtRisk":72},{"groupId":"EG002","numAffected":44,"numAtRisk":45},{"groupId":"EG003","numAffected":18,"numAtRisk":53},{"groupId":"EG004","numAffected":17,"numAtRisk":18},{"groupId":"EG005","numAffected":36,"numAtRisk":37},{"groupId":"EG006","numAffected":17,"numAtRisk":18},{"groupId":"EG007","numAffected":5,"numAtRisk":27}]},{"term":"Injection site warmth","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":2,"numAtRisk":72},{"groupId":"EG002","numAffected":2,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":1,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":45},{"groupId":"EG001","numAffected":13,"numAtRisk":72},{"groupId":"EG002","numAffected":10,"numAtRisk":45},{"groupId":"EG003","numAffected":1,"numAtRisk":53},{"groupId":"EG004","numAffected":4,"numAtRisk":18},{"groupId":"EG005","numAffected":9,"numAtRisk":37},{"groupId":"EG006","numAffected":8,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Asymptomatic COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":2,"numAtRisk":27}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":45},{"groupId":"EG001","numAffected":4,"numAtRisk":72},{"groupId":"EG002","numAffected":3,"numAtRisk":45},{"groupId":"EG003","numAffected":3,"numAtRisk":53},{"groupId":"EG004","numAffected":1,"numAtRisk":18},{"groupId":"EG005","numAffected":2,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":1,"numAtRisk":27}]},{"term":"Gingivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":1,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":1,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":1,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":72},{"groupId":"EG002","numAffected":1,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":2,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":1,"numAtRisk":27}]},{"term":"Pharyngitis streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":2,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":2,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":45},{"groupId":"EG001","numAffected":2,"numAtRisk":72},{"groupId":"EG002","numAffected":1,"numAtRisk":45},{"groupId":"EG003","numAffected":1,"numAtRisk":53},{"groupId":"EG004","numAffected":3,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":1,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":72},{"groupId":"EG002","numAffected":1,"numAtRisk":45},{"groupId":"EG003","numAffected":3,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Muscle strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":1,"numAtRisk":53},{"groupId":"EG004","numAffected":1,"numAtRisk":18},{"groupId":"EG005","numAffected":1,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":2,"numAtRisk":72},{"groupId":"EG002","numAffected":2,"numAtRisk":45},{"groupId":"EG003","numAffected":1,"numAtRisk":53},{"groupId":"EG004","numAffected":1,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Activated partial thromboplastin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":2,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":3,"numAtRisk":53},{"groupId":"EG004","numAffected":1,"numAtRisk":18},{"groupId":"EG005","numAffected":2,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":1,"numAtRisk":27}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":45},{"groupId":"EG001","numAffected":1,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":2,"numAtRisk":53},{"groupId":"EG004","numAffected":2,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Differential white blood cell count abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":1,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":7,"numAtRisk":72},{"groupId":"EG002","numAffected":1,"numAtRisk":45},{"groupId":"EG003","numAffected":1,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":4,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":1,"numAtRisk":27}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":2,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":1,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Prothrombin time prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":2,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":2,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":1,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":45},{"groupId":"EG001","numAffected":39,"numAtRisk":72},{"groupId":"EG002","numAffected":20,"numAtRisk":45},{"groupId":"EG003","numAffected":10,"numAtRisk":53},{"groupId":"EG004","numAffected":12,"numAtRisk":18},{"groupId":"EG005","numAffected":27,"numAtRisk":37},{"groupId":"EG006","numAffected":9,"numAtRisk":18},{"groupId":"EG007","numAffected":2,"numAtRisk":27}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":45},{"groupId":"EG001","numAffected":52,"numAtRisk":72},{"groupId":"EG002","numAffected":29,"numAtRisk":45},{"groupId":"EG003","numAffected":11,"numAtRisk":53},{"groupId":"EG004","numAffected":14,"numAtRisk":18},{"groupId":"EG005","numAffected":29,"numAtRisk":37},{"groupId":"EG006","numAffected":15,"numAtRisk":18},{"groupId":"EG007","numAffected":5,"numAtRisk":27}]},{"term":"Synovial cyst","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":1,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":45},{"groupId":"EG001","numAffected":48,"numAtRisk":72},{"groupId":"EG002","numAffected":30,"numAtRisk":45},{"groupId":"EG003","numAffected":29,"numAtRisk":53},{"groupId":"EG004","numAffected":14,"numAtRisk":18},{"groupId":"EG005","numAffected":33,"numAtRisk":37},{"groupId":"EG006","numAffected":15,"numAtRisk":18},{"groupId":"EG007","numAffected":15,"numAtRisk":27}]},{"term":"Restless legs syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":1,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":1,"numAtRisk":18},{"groupId":"EG007","numAffected":1,"numAtRisk":27}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":2,"numAtRisk":72},{"groupId":"EG002","numAffected":3,"numAtRisk":45},{"groupId":"EG003","numAffected":1,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":1,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":1,"numAtRisk":27}]},{"term":"Polycystic ovaries","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":21},{"groupId":"EG001","numAffected":0,"numAtRisk":50},{"groupId":"EG002","numAffected":0,"numAtRisk":24},{"groupId":"EG003","numAffected":0,"numAtRisk":37},{"groupId":"EG004","numAffected":1,"numAtRisk":12},{"groupId":"EG005","numAffected":0,"numAtRisk":29},{"groupId":"EG006","numAffected":0,"numAtRisk":12},{"groupId":"EG007","numAffected":0,"numAtRisk":21}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":1,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Pain of skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":1,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Papule","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":45},{"groupId":"EG001","numAffected":0,"numAtRisk":72},{"groupId":"EG002","numAffected":0,"numAtRisk":45},{"groupId":"EG003","numAffected":0,"numAtRisk":53},{"groupId":"EG004","numAffected":1,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":0,"numAtRisk":18},{"groupId":"EG007","numAffected":0,"numAtRisk":27}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":45},{"groupId":"EG001","numAffected":3,"numAtRisk":72},{"groupId":"EG002","numAffected":2,"numAtRisk":45},{"groupId":"EG003","numAffected":2,"numAtRisk":53},{"groupId":"EG004","numAffected":0,"numAtRisk":18},{"groupId":"EG005","numAffected":0,"numAtRisk":37},{"groupId":"EG006","numAffected":1,"numAtRisk":18},{"groupId":"EG007","numAffected":1,"numAtRisk":27}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Moderna Clinical Trials Support Center","organization":"ModernaTX, Inc.","email":"clinicaltrials@modernatx.com","phone":"1-877-777-7187"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-05-27","uploadDate":"2025-12-18T10:05","filename":"Prot_000.pdf","size":3050581},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2023-04-03","uploadDate":"2025-12-18T10:05","filename":"SAP_001.pdf","size":1089603}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2026-01-12","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D003586","term":"Cytomegalovirus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D004266","term":"DNA Virus Infections"}],"ancestors":[{"id":"D006566","term":"Herpesviridae Infections"},{"id":"D007239","term":"Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"C000722750","term":"mRNA-1647 cytomegalovirus vaccine"}]}},"hasResults":true}